[{"text": "Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m Investment editorial-team@simplywallst.com (Simply Wall St) Sat, Jan 18, 2025, 3:21 PM 3 min read In This Article: CADL +1.13% Candel Therapeutics, Inc. ( NASDAQ:CADL ) insiders who acquired shares over the previous 12 months, can probably afford to ignore the recent 19% decline in the stock price. After accounting for the recent loss, the US$3.00m worth of shares they purchased is now worth US$3.33m, suggesting a good return on their investment. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether. See our latest analysis for Candel Therapeutics The Last 12 Months Of Insider Transactions At Candel Therapeutics Over the last year, we can see that the biggest insider purchase was by Independent Chairman Paul Manning for US$3.0m worth of shares, at about US$6.00 per share. That means that an insider was happy to buy shares at around the current price of US$6.67. That means they have been optimistic about the company in the past, though they may have changed their mind. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Candel Therapeutics insider decided to buy shares at close to current prices. Paul Manning was the only individual insider to buy shares in the last twelve months. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction! NasdaqGM:CADL Insider Trading Volume January 18th 2025 Candel Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying. Insiders At Candel Therapeutics Have Bought Stock Recently At Candel Therapeutics,over the last quarter, we have observed quite a lot more insider buying than insider selling. Independent Chairman Paul Manning spent US$3.0m on stock. On the other hand, insiders netted US$1.6m by selling. We think insiders may be optimistic about the future, since insiders have been net buyers of shares. Does Candel Therapeutics Boast High Insider Ownership? I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 13% of Candel Therapeutics shares, worth about US$32m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders. Story Continues So What Does This Data Suggest About Candel Therapeutics Insiders? It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of Candel Therapeutics we think they are probably pretty confident of a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Candel Therapeutics. Every company has risks, and we've spotted 5 warning signs for Candel Therapeutics (of which 4 don't sit too well with us!) you should know about. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CADL", "date": "2025-01-18T12:21:17+00:00", "sentiment": {"score": -0.004527725279331207, "confidence": 0.046330615878105164, "probabilities": {"positive": 0.041802890598773956, "negative": 0.046330615878105164, "neutral": 0.9118664860725403}}, "embedding": [-0.05126693844795227, -0.10417325794696808, -0.019886765629053116, -0.01974622718989849, -0.012732576578855515, -0.002666379325091839, 0.10470494627952576, 0.13841113448143005, 0.17697419226169586, 0.11596187204122543, 0.02018139511346817, 0.1263311505317688, 0.1362970471382141, -0.049195267260074615, -0.06099032238125801, -0.011973478831350803, 0.02335895225405693, 0.05831221118569374, -0.13682332634925842, 0.14573974907398224, -0.2897213101387024, -0.1750439703464508, -0.0226850975304842, 0.027383556589484215, 0.1276453733444214, -0.010020393878221512, -0.0574600026011467, -0.0751991719007492, -0.11269039660692215, -0.10397431254386902, -0.05732470005750656, 0.06453537195920944, 0.0027630121912807226, -0.007275926880538464, -0.056477464735507965, -0.011158805340528488, -0.08253975212574005, 0.053519099950790405, 0.016537001356482506, -0.08017567545175552, 0.06670695543289185, 0.025174662470817566, -0.0013177013024687767, -0.024601085111498833, -0.14767563343048096, -0.11836931854486465, -0.03370417281985283, -0.0007908663246780634, 0.09871850907802582, -0.031551338732242584, -0.04405646771192551, -0.05961509048938751, 0.12201952934265137, -0.10044605284929276, 0.013274187222123146, 0.10019026696681976, -0.06262896955013275, -0.09006476402282715, -0.0024877008982002735, 0.06559160351753235, 0.05103389173746109, -0.010345805436372757, -0.030627820640802383, -0.028216971084475517, 0.1850651204586029, -0.06781267374753952, 0.06993648409843445, 0.008642632514238358, 0.042332060635089874, -0.0726453885436058, 0.2608034610748291, -0.06881236284971237, -0.05441949516534805, -0.11471903324127197, -0.10416285693645477, 0.008154956623911858, 0.1612284779548645, 0.14488691091537476, 0.020090376958251, -0.06522324681282043, -0.008337058126926422, 0.12208837270736694, -0.024599093943834305, -0.07820399105548859, -0.07363836467266083, 0.06229753792285919, 0.019515659660100937, 0.12673386931419373, 0.05952376127243042, 0.06883712857961655, 0.06994159519672394, -0.03196252882480621, -0.12339562922716141, -0.023913217708468437, 0.03199845552444458, 0.06846381723880768, -0.09996664524078369, 0.19195303320884705, -0.01033550500869751, 0.017917662858963013, 0.15334917604923248, 0.14441251754760742, 0.012119820341467857, -0.08025018870830536, 0.006767233368009329, -0.09202136099338531, 0.05544177442789078, -0.07512664794921875, 0.05434219911694527, 0.03454269841313362, -0.19912156462669373, -0.053053490817546844, -0.14521341025829315, -0.021991746500134468, -0.0417226105928421, 0.041485607624053955, 0.02724028192460537, -0.08074196428060532, 0.09519404172897339, -0.05337343364953995, 0.07096265256404877, 0.11973413825035095, 0.019799627363681793, 0.017592662945389748, -0.1259440779685974, 0.05724569037556648, -0.03397740051150322, 1.153234895921529e-32, -0.009217116981744766, 0.032236211001873016, -0.008199267089366913, 0.0246841162443161, -0.009521717205643654, 0.045930854976177216, 0.10365300625562668, -0.12360545992851257, -0.0792638286948204, -0.037518229335546494, -0.10369334369897842, 0.06917785108089447, -0.06385623663663864, -0.008069087751209736, -0.14749501645565033, -0.08396926522254944, -0.04978829249739647, -0.015357987023890018, -0.02857866883277893, -0.06179318577051163, 0.05497527867555618, 0.12649942934513092, -0.07578513026237488, 0.016426384449005127, -0.044924139976501465, -0.0593474879860878, -0.062230490148067474, -0.0101430369541049, 0.06874357163906097, 0.003918341360986233, 0.0032157418318092823, 0.036909785121679306, 0.016936160624027252, 0.03323584794998169, 0.0326535664498806, 0.07042190432548523, -0.04572286829352379, -0.04242638871073723, 0.09173780679702759, -0.01167425699532032, -0.05271963030099869, 0.1253156214952469, -0.07381144165992737, -0.17808277904987335, -0.08161433041095734, 0.017286241054534912, -0.08609931170940399, 0.07480251789093018, 0.02881045825779438, -0.13735808432102203, 0.11927539110183716, 0.11067028343677521, 6.486475467681885e-05, -0.1270246058702469, -0.032457102090120316, 0.0572512187063694, 0.06808032095432281, -0.038799941539764404, 0.056607142090797424, 0.20795348286628723, -0.006475532427430153, 0.15376493334770203, 0.044192761182785034, 0.11007396876811981, -0.2319616973400116, 0.12988469004631042, -0.06383491307497025, 0.0992773249745369, -0.08226737380027771, 0.13135729730129242, -0.07841959595680237, 0.061148062348365784, 0.08415570855140686, -0.1149836853146553, 0.02349129691720009, 0.00881336908787489, 0.02664163149893284, 0.007826555520296097, 0.06458287686109543, 0.03675888478755951, 0.014341914094984531, -0.005087141878902912, 0.03000042214989662, 0.1422363817691803, -0.06310001015663147, 0.05731235817074776, -0.0007534213364124298, 0.04054028540849686, -0.0781293734908104, 0.0935416966676712, 0.12720313668251038, -0.007850061170756817, 0.030361849814653397, 0.10544785857200623, -0.05632580444216728, -1.3487645691221943e-32, -0.12237654626369476, 0.044715799391269684, 0.021594364196062088, -0.2544439435005188, 0.03269307687878609, -0.011384770274162292, -0.007902855053544044, 0.0613739937543869, -0.039397358894348145, -0.04306996613740921, -0.014166504144668579, 0.014437844976782799, -0.008793013170361519, 0.0781862884759903, -0.1304212361574173, -0.016730397939682007, 0.018698416650295258, -0.013760147616267204, 0.011271469295024872, -0.09925806522369385, 0.009349964559078217, 0.19576583802700043, -0.13464757800102234, 0.11888115853071213, -0.01621212624013424, 0.07613298296928406, 0.006039973348379135, 0.1992640644311905, -0.035168200731277466, -0.014454381540417671, 0.0184268020093441, -0.043980590999126434, -0.11935919523239136, 0.040022484958171844, 0.06885764747858047, 0.0013993196189403534, -0.014907244592905045, -0.035826362669467926, 0.017833402380347252, -0.07797299325466156, 0.02004697546362877, 0.0722799226641655, 0.0417092964053154, -0.07909694314002991, 0.130532369017601, 0.0028564194217324257, -0.021203111857175827, -0.26204991340637207, 0.09832526743412018, 0.11840853095054626, -0.06613929569721222, -0.0380261093378067, 0.05774950236082077, 0.15802347660064697, -0.1639033854007721, 0.04663778096437454, 0.07634828239679337, 0.041758663952350616, 0.21691524982452393, -0.09824240207672119, -0.08851708471775055, 0.18630746006965637, -0.03016076609492302, 0.014343048445880413, -0.09197213500738144, -0.0014169680653139949, -0.05698123946785927, -0.21140369772911072, -0.23879656195640564, -0.11264632642269135, -0.013639305718243122, -0.13470938801765442, -0.006901811808347702, -0.1616455316543579, 0.04622683674097061, 0.27440977096557617, -0.11166823655366898, -0.16035187244415283, -0.06305090337991714, -0.008094793185591698, 0.05060398578643799, -0.04526745155453682, 0.06498704850673676, 0.04350339621305466, -0.017252463847398758, 0.037603773176670074, 0.06375784426927567, -0.010118097066879272, -0.040042221546173096, -0.04297752305865288, -0.10777755826711655, -0.2589177191257477, -0.06557387113571167, -0.10245713591575623, 0.02567283809185028, -1.005463019509989e-07, -0.03167561814188957, -0.0483773835003376, -0.04715394228696823, -0.02004489302635193, 0.09782781451940536, -0.06365375220775604, 0.028798267245292664, -0.03845065087080002, 0.05324468016624451, 0.24291342496871948, 0.1726447343826294, -0.030750233680009842, -0.25467848777770996, -0.02758685313165188, -0.06731747090816498, 0.014823850244283676, -0.05721239745616913, -0.0736776739358902, -0.04174618050456047, -0.06694741547107697, -0.07028814405202866, 0.18040472269058228, 0.103981152176857, -0.004942907951772213, 0.003487285226583481, 0.02172071859240532, -0.060451313853263855, 0.1788332760334015, -0.02870500274002552, 0.06845687329769135, 0.050337307155132294, -0.005592692643404007, 0.043387025594711304, 0.08526267111301422, -0.05675327777862549, 0.03089933469891548, 0.035598866641521454, 0.09291934967041016, -0.03938278928399086, 0.17601005733013153, -0.0640738233923912, -0.13378919661045074, -0.031651850789785385, -0.024399444460868835, -0.029501721262931824, -0.04580783098936081, -0.19135022163391113, -0.039855293929576874, 0.03722519427537918, -0.08988821506500244, 0.1901741921901703, -0.1295289546251297, 0.0626300647854805, 0.040648624300956726, 0.012223884463310242, 0.03651430457830429, -0.11070600152015686, 0.13674983382225037, -0.20850437879562378, -0.040544863790273666, -0.09142990410327911, -0.18819460272789001, 0.0772620141506195, 0.15181373059749603], "changes": {"1wk": 4.314910622090924}}, {"text": "Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025 Candel Therapeutics Mon, Jan 13, 2025, 4:00 PM 14 min read In This Article: CADL +1.13% Candel Therapeutics On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025 Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026 The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025 The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027 NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company\u2019s cash position and upcoming 2025 milestones. \u201cI am incredibly proud of the Candel team for their successful execution of our 2024 priorities,\u201d said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. \u201cWe demonstrated substantial clinical activity for our investigational medicines and delivered strong results across our pipeline, including positive and pivotal topline phase 3 data for CAN-2409 in intermediate-to-high risk localized prostate cancer, positive topline overall survival data from the phase 2a randomized controlled clinical trial of CAN-2409 in borderline resectable PDAC, as well as topline overall survival data from the open label phase 2a clinical trial of CAN-2409 in patients with stage III/IV NSCLC. We have also reported initial clinical and biomarker activity after repeated injection of CAN-3110 in the ongoing phase 1b clinical trial in rHGG and encouraging data demonstrating CAN-3110\u2019s potential in a second indication, in a model of melanoma. In 2024, we also presented data on two novel experimental assets generated using Candel\u2019s enLIGHTEN\u2122 Discovery Platform. During the 2024 American Association for Cancer Research (AACR) Annual Meeting, we reported preclinical data for the first-in-class, tertiary lymphoid structure (TLS) inducer viral immunotherapy, and during the 2024 International Oncolytic Virotherapy Conference (IOVC), we presented data on a multimodal immunotherapy that delivers interleukin-12 (IL-12) and interleukin-15 (IL-15) to the tumor microenvironment.\u201d Story Continues Dr. Tak continued, \u201cWe are entering 2025 with clear momentum. Our primary focus will be achieving BLA readiness for CAN-2409 in prostate cancer. If approved, we believe that CAN-2409 has the potential to become a first-line treatment, as an addition to radiation therapy to reduce the risk of recurrence of prostate cancer, and to redefine the current standard-of-care for prostate cancer patients. In the upcoming months we look forward to collaborating closely with the FDA to ensure alignment in preparation for our BLA submission which, if approved, would enable us to deliver this much-needed therapy to patients.\u201d 2024 Accomplishments CAN-2409 \u2013 Prostate Cancer In December 2024, the Company reported positive topline data from its multicenter phase 3 clinical trial evaluating CAN-2409 in intermediate-to-high-risk localized prostate cancer patients. The study met its primary endpoint by demonstrating statistically significant improvement in disease-free survival (DFS) in patients who received CAN-2409 plus valacyclovir (prodrug) combined with standard of care (SoC) external beam radiation therapy (n=496) compared to standard of care alone (n=249) in the intent to treat population. The data showed a 30% reduction in the risk for prostate cancer recurrence or death due to any cause for the CAN-2409 treatment arm compared to placebo control arm (p=0.0155), and 80.4% pathological complete responses in 2-year post-treatment biopsies after CAN-2409 administration compared to 63.6% in the control arm (p=0.0015). The safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identified. This study was conducted under a Special Protocol Assessment (SPA) with U.S. Food and Drug Administration (FDA) agreement on key aspects of study design, meaning that safety and efficacy data generated from the study could be sufficient for the Company to seek regulatory approval for CAN-2409 in this indication. FDA previously granted Fast Track Designation for CAN-2409 for the treatment of prostate cancer. CAN-2409 - Pancreatic Cancer In April 2024, the Company announced positive updated survival data from the phase 2a randomized controlled clinical trial of CAN-2409 plus valacyclovir (prodrug), together with SoC chemoradiation, in borderline resectable PDAC (n=13). The data showed notable improvements in estimated median overall survival (mOS) of 28.8 months after experimental treatment with CAN-2409 versus 12.5 months in control group. At 24 months, the survival rate was 71.4% in CAN-2409-treated patients versus 16.7% in the control group. At 36 months, estimated survival was 47.6% in the CAN-2409 group versus 16.7% in the control group. FDA previously granted Fast Track Designation for CAN-2409 in borderline resectable PDAC. FDA granted Orphan Drug Designation for CAN-2409 in borderline resectable PDAC in April 2024. CAN-2409 \u2013 Non-Small Cell Lung Cancer At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the Company presented topline overall survival data from the phase 2a clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor (ICI) therapy in patients with stage III/IV NSCLC inadequately responding to ICI therapy. The data (as of April 1, 2024) showed mOS of 20.6 months in patients with progressive disease (n=41) despite ICI treatment compared to published results of less than 12 months with SoC docetaxel-based chemotherapy in similar patient populations. As of the data cut-off date, CAN-2409 treatment in NSCLC continued to exhibit a favorable safety and tolerability profile. FDA previously granted Fast Track Designation for CAN-2409 for the treatment of NSCLC. CAN-3110 \u2013 Recurrent High-Grade Glioma Presented a Trial-in-Progress poster at the 2024 ASCO Annual Meeting on the ongoing phase 1b clinical trial exploring multiple doses of CAN-3110 in patients with rHGG. Presented updated clinical and biomarker activity data at the IOVC in October 2024. Investigators reported ongoing improved survival compared to historical controls, with 3 out of 6 patients still alive after more than one year (12.2, 13.0, and 18.7 months, respectively) after initiation of experimental treatment with repeated CAN-3110 injections. FDA granted Orphan Drug Designation for CAN-3110 for treatment of rHGG in May 2024. FDA granted Fast Track Designation for CAN-3110 for the treatment of rHGG in February 2024. CAN-3110 \u2013 Melanoma Presented preclinical results on the therapeutic potential of CAN-3110 in the Ras-Raf pathway altered melanoma model at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting. CAN-3110 exhibited potent, tumor-specific cytotoxicity in human and murine melanoma cell lines with varied CDKN2A pathway alterations and Nestin expression. In vivo mouse studies showed dose-dependent inhibition of tumor growth, with regression observed in a subset (3 of 8) of tumors treated with a high dose of CAN-3110. The therapy was well-tolerated in preclinical mouse models based on body weight and histopathological analysis following intra-tumoral administration. enLIGHTEN \u2122 Discovery Platform Presented data on a new multimodal viral therapeutic candidate encoding IL-12 and IL-15 at the 2024 IOVC. Data showed the ability of the asset to induce expansion and activation of natural killer and CD8+ T cell populations, resulting in significant tumor growth inhibition and tumor regression in two different models. Presented data at the AACR 2024 Annual Meeting describing a first-in-class, multimodal immunotherapy candidate for the induction of tertiary lymphoid structures, being developed as a novel therapeutic strategy for solid tumors. Delivery of two unique payload combinations, predicted in silico using the enLIGHTEN\u2122 Advanced Analytics suite, was shown to induce TLS formation, inhibit tumor growth, and improve response to ICI therapy in preclinical models of cancer. 2025 Anticipated Milestones and Key Catalysts CAN-2409 \u2013 Pancreatic Cancer Updated overall survival data from phase 2a clinical trial, expected in Q1 2025 Preparations underway for potential phase 2b, randomized clinical trial CAN-2409 \u2013 Non-Small Cell Lung Cancer Updated overall survival data from phase 2a clinical trial, expected in Q1 2025 Preparations underway for potential phase 2b, randomized clinical trial CAN-2409 \u2013 Prostate Cancer Presentation of the phase 3 clinical trial data at upcoming scientific conference Publication of the phase 3 clinical trial data in a scientific journal BLA submission on track for Q4 2026 CAN-3110 \u2013 Recurrent High-Grade Glioma Overall survival data from ongoing phase 1b clinical trial evaluating multiple doses, expected in Q4 2025 Cash Position Cash and cash equivalents, as of December 31, 2024, were $102.9 million (unaudited), as compared to $35.4 million (audited) as of December 31, 2023. Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will support the preparation and submission of a BLA for CAN-2409 in prostate cancer, as well as fund its current operating plan into Q1 2027. About CAN-2409 CAN-2409, Candel\u2019s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient\u2019s specific tumor and induce an individualized, systemic immune response against the tumor. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ vaccination against a variety of tumor antigens. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several preclinical and clinical settings. More than 1,000 patients have been dosed with CAN-2409 with a favorable tolerability profile to date, supporting the potential for combination with other therapeutic strategies. Currently, Candel is evaluating CAN-2409 in NSCLC, and borderline resectable PDAC, in ongoing clinical trials, and has recently completed phase 2b and phase 3 clinical trials in localized, non-metastatic prostate cancer. CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. Candel\u2019s pivotal phase 3 clinical trial in prostate cancer was conducted under a Special Protocol Assessment agreed with the FDA. The FDA has also granted Orphan Drug Designation to CAN-2409 for the treatment of PDAC. About CAN-3110 CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. CAN-3110 is being evaluated in a phase 1b clinical trial in patients with rHGG. In October 2023, the Company announced that Nature published results from this ongoing clinical trial. CAN-3110 was well tolerated with no dose-limiting toxicity reported. In the clinical trial, the investigators observed improved median overall survival compared to historical controls after a single CAN-3110 injection in this therapy-resistant condition. 1 The Company and academic collaborators are currently evaluating the effects of multiple CAN-3110 injections in rHGG, supported by the Break Through Cancer foundation. CAN-3110 has previously received FDA Fast Track Designation and Orphan Drug Designation for the treatment of rHGG. About the enLIGHTEN\u2122 Discovery Platform The enLIGHTEN\u2122 Discovery Platform is a systematic, iterative herpes simplex virus (HSV)-based discovery platform leveraging human biology and advanced analytics to create new multimodal biological immunotherapies for solid tumors. The enLIGHTEN\u2122 Discovery Platform has been designed to deconvolute the characteristics of the tumor microenvironment related to clinical outcomes. These characteristics are rapidly translated into optimized multi-gene payloads of tumor modulators that can be delivered to the tumor microenvironment for specific indications, disease stages, and rationally designed therapeutic combinations. In 2022, the Company announced a discovery partnership with the University of Pennsylvania Center for Cellular Immunotherapies to create new viral immunotherapies that could enhance the efficacy of chimeric antigen receptor T cell (CAR-T) therapy in solid tumors. During the SITC 2023 Annual Meeting and the 2023 IOVC meeting, Candel presented encouraging data on the first candidate from this platform, Alpha 201-macro-1, which was designed to interfere with the CD47/SIRP1\u03b1 pathway, in mouse models of breast cancer and lung cancer. During the AACR Annual Meeting 2024, Candel presented preclinical data, unveiling the second candidate from the enLIGHTEN\u2122 Discovery Platform, a first-in-class multimodal immunotherapy candidate to induce TLS, being developed as a novel therapeutic for solid tumors. Candel presented data at the 2024 IOVC meeting. The presentation focused on a multimodal viral therapeutic candidate encoding IL-12 and IL-15, the latest asset from the platform. About Candel Therapeutics Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and HSV gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in NSCLC (phase 2) and borderline resectable PDAC (phase 2) and recently completed phase 2b and phase 3 clinical trials in localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in rHGG. Finally, Candel\u2019s enLIGHTEN\u2122 Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: www.candeltx.com Forward-Looking Statements This press release includes certain disclosures that contain \u201cforward-looking statements,\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, including key data readout milestones and presentations; expectations regarding early biological readouts as predictor of clinical response; expectations regarding the therapeutic benefit of the Company\u2019s programs, including the ability of CAN-2409 to improve overall survival of patients with intermediate-to-high-risk localized prostate cancer, NSCLC, and pancreatic cancer and the ability of CAN-3110 to treat rHGG and melanoma; the ability of our enLIGHTEN TM Discovery Platform to identify new candidates with the potential to alter the lives of patients living with difficult to treat, solid tumors; expectations regarding the potential benefits conferred by orphan drug designation and fast track designation; and expectations regarding cash runway and expenditures. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; the Company\u2019s ability to continue as a going concern; expectations regarding the therapeutic benefit of the Company\u2019s programs; that final data from the Company\u2019s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company\u2019s ability to efficiently discover and develop product candidates; the Company\u2019s ability to obtain and maintain regulatory approval of product candidates; the Company\u2019s ability to maintain its intellectual property; the implementation of the Company\u2019s business model, including strategic plans for the Company\u2019s business and product candidates; and other risks identified in the Company\u2019s filings with the U.S. Securities and Exchange Commission (SEC) including the Company\u2019s most recent Quarterly Report on Form 10-Q filed with the SEC and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company\u2019s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact Theodore Jenkins Vice President, Investor Relations, and Business Development Candel Therapeutics, Inc. tjenkins@candeltx.com Media Contact Ben Shannon Vice President ICR Healthcare CandelPR@icrhealthcare.com 1 Ling AL, et al. Nature. 2023;623(7985):157-166. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CADL", "date": "2025-01-13T13:00:00+00:00", "sentiment": {"score": 0.9036134267225862, "confidence": 0.9132211208343506, "probabilities": {"positive": 0.9132211208343506, "negative": 0.009607694111764431, "neutral": 0.07717113941907883}}, "embedding": [-0.1731567680835724, -0.08825445920228958, -0.098886638879776, -0.2137070596218109, -0.05334087461233139, -0.11764594167470932, -0.10438913106918335, 0.11263655871152878, 0.08064664155244827, 0.08304640650749207, -0.09279154241085052, 0.042388685047626495, 0.04837986081838608, 0.12650124728679657, -0.0747993215918541, 0.053508467972278595, 0.0887625589966774, -0.05498462915420532, -0.13394396007061005, 0.11925849318504333, 0.020775459706783295, 0.018460702151060104, 0.020605705678462982, 0.13606947660446167, -0.002896512858569622, -0.11372159421443939, -0.09105214476585388, -0.023535285145044327, -0.15344735980033875, -0.1417309045791626, 0.12239838391542435, 0.04890037328004837, -0.07141777127981186, -0.02567358687520027, 0.08712472766637802, -0.07268090546131134, -0.11678332090377808, 0.022924814373254776, -0.08731187880039215, -0.07702738046646118, -0.04847869277000427, -0.0879393219947815, -0.13037127256393433, 0.06497135758399963, 0.05850345641374588, -0.2434176206588745, -0.1183646097779274, -0.015222713351249695, 0.07275718450546265, 0.21777701377868652, -0.056070152670145035, -0.08930948376655579, 0.01647256128489971, 0.13158831000328064, 0.006837925873696804, -0.007296402007341385, -0.1252298355102539, -0.014377879910171032, -0.0373060442507267, 0.04596732556819916, -0.013914871029555798, -0.12668171525001526, -0.07917332649230957, 0.0402601957321167, 0.07890302687883377, 0.018009237945079803, -0.06644521653652191, -0.0566849559545517, -0.06875602900981903, 0.00984373688697815, 0.11663620173931122, -0.08931288868188858, 0.03153518587350845, 0.03212176263332367, -0.036790572106838226, 0.06614898145198822, 0.14826801419258118, 0.20888680219650269, 0.10358062386512756, -0.1820281744003296, 0.09759420901536942, 0.03564118966460228, -0.00875678937882185, -0.06285218149423599, -0.02152976766228676, -0.048525236546993256, -0.056465692818164825, 0.2764892578125, 0.0872792974114418, -0.022885147482156754, 0.142581507563591, 0.04732847213745117, 0.04322211444377899, 0.07538184523582458, -0.08397017419338226, -0.048525162041187286, -0.02124408446252346, -0.04490696266293526, 0.1199992448091507, -0.058555811643600464, 0.05453040450811386, -0.0026642614975571632, -0.04870111122727394, -0.17605465650558472, -0.10606546700000763, -0.11520245671272278, 0.01713082753121853, -0.049822937697172165, 0.06963184475898743, 0.038825780153274536, -0.05391279608011246, 0.0060655660927295685, 0.08609750866889954, 0.02180919423699379, -0.056699417531490326, 0.14599201083183289, -0.12886793911457062, -0.019097406417131424, 0.07641123980283737, -0.08657719194889069, -0.022198373451828957, 0.011831944808363914, 0.021857136860489845, -0.12724845111370087, 0.03250832483172417, 0.15211106836795807, -0.06160707026720047, 1.4146832066436373e-32, 0.05833704024553299, 0.04176587983965874, 0.04125857725739479, 0.08594177663326263, 0.009453491307795048, 0.017434313893318176, 0.18936529755592346, -0.0198458731174469, -0.18017873167991638, -0.18817241489887238, 0.01168961450457573, 0.050828300416469574, -0.02436058409512043, 0.009704161435365677, -0.1685539335012436, -0.07755954563617706, 0.023836353793740273, 0.03687569126486778, -0.10545909404754639, 0.017062703147530556, 0.10342113673686981, 0.025103535503149033, -0.07337532937526703, -0.023045245558023453, -0.006927871610969305, 0.1672379970550537, -0.036063358187675476, 0.11318936944007874, 0.1098041832447052, 0.05352577567100525, -0.09607759118080139, 0.07245641201734543, -0.006738650146871805, -0.09208056330680847, -0.028321707621216774, -0.03252154588699341, 0.03351878374814987, -0.07117503881454468, 0.1386781930923462, 0.07840912789106369, 0.08233393728733063, 0.08817467093467712, -0.03313950076699257, -0.15892520546913147, -0.06099747121334076, -0.08268926292657852, -0.024289820343255997, 0.05350783094763756, -0.06154128164052963, 0.021658414974808693, -0.019873155280947685, -0.03264923021197319, -0.08034493774175644, 0.009283563122153282, -0.03168312460184097, 0.015951309353113174, -0.139101043343544, -0.02645290642976761, 0.060965731739997864, 0.12747254967689514, 0.017892491072416306, 0.052701469510793686, -0.017645418643951416, 0.0036422908306121826, -0.10773532837629318, 0.10320071876049042, -0.08647168427705765, -0.0005808371352031827, -0.04189483821392059, 0.21766844391822815, -0.05365034565329552, 0.041185226291418076, 0.16382528841495514, -0.002285973634570837, 0.13432610034942627, -0.14030329883098602, 0.11450646072626114, 0.037066567689180374, -0.044903695583343506, 0.1423872858285904, -0.07084670662879944, 0.03355083614587784, -0.17877738177776337, 0.18841278553009033, -0.017327019944787025, -0.09017381072044373, 0.09061595797538757, 0.0038941334933042526, -0.29404401779174805, -0.06772849708795547, 0.14180903136730194, -0.05176085606217384, 0.10432624816894531, 0.10041344165802002, -0.019297845661640167, -1.615400777224863e-32, 0.08238516747951508, 0.0409272238612175, 0.08344709873199463, -0.12084619700908661, 0.10562264919281006, 0.0882711410522461, 0.10598994791507721, -0.052833788096904755, 0.09612643718719482, -0.09470512717962265, 0.057031355798244476, 0.0693235769867897, 0.006379328668117523, -0.01912105455994606, -0.13260909914970398, -0.1092945784330368, -0.1139184981584549, -0.1672467589378357, -0.14973650872707367, -0.005711215548217297, 0.00020214621326886117, 0.15305623412132263, -0.13676303625106812, 0.14432860910892487, -0.13583461940288544, 0.09791270643472672, 0.06082314997911453, 0.03952550143003464, 0.1295938640832901, -0.03366990387439728, -0.013487528078258038, 0.05040578544139862, -0.2954932153224945, -0.01696694642305374, -0.004336231388151646, -0.018783848732709885, 0.133402481675148, -0.1603708416223526, -0.06483036279678345, -0.07098671793937683, 0.019989455118775368, 0.0999545231461525, -0.10572116076946259, -0.009661372750997543, 0.03156225383281708, 0.030217193067073822, 0.11459556967020035, -0.07943374663591385, 0.21549785137176514, 0.04900673031806946, 0.00868220254778862, -0.048823289573192596, -0.010096125304698944, 0.13854306936264038, -0.05153677612543106, -0.0748320072889328, 0.0226345993578434, -0.0953158587217331, -0.02559272199869156, -0.04632868990302086, -0.07376942038536072, 0.1487974226474762, -0.027470575645565987, 0.029405172914266586, 0.027316248044371605, 0.10578002035617828, 0.03312859684228897, -0.15687960386276245, 0.008883319795131683, -0.01678266003727913, -0.13503438234329224, -0.05866345018148422, 0.019768554717302322, -0.03689024597406387, 0.019773069769144058, 0.1032109409570694, -0.006753887981176376, -0.24769356846809387, -0.06461875885725021, -0.09207069128751755, -0.005211733281612396, -0.10393573343753815, -0.05500546842813492, 0.039038363844156265, 0.2040194869041443, 0.05768110603094101, 0.022723089903593063, -0.058655451983213425, -0.0028082411736249924, 0.07704389095306396, -0.12270589172840118, -0.04384277015924454, -0.043165020644664764, 0.14228539168834686, 0.024934984743595123, -1.010913877053099e-07, 0.06052052229642868, -0.05727123096585274, -0.04066791757941246, -0.10841679573059082, -0.04279613122344017, 0.033760230988264084, -0.014085127040743828, 0.005637684836983681, 0.15974107384681702, 0.12882393598556519, 0.2038138210773468, 0.13007546961307526, -0.15714599192142487, -0.03899902105331421, -0.15918633341789246, 0.07652539014816284, 0.0063244132325053215, -0.04650645703077316, 0.016472917050123215, -0.07256379723548889, -0.18060782551765442, 0.036027103662490845, -0.018454087898135185, -0.08314258605241776, 0.016005542129278183, -0.026718690991401672, 0.01773385889828205, 0.1961720585823059, 0.027565935626626015, -0.08260687440633774, -0.08106398582458496, -0.11742796003818512, 0.0943390503525734, 0.08897042274475098, 0.0706140324473381, -0.13523027300834656, 0.097246915102005, 0.20520058274269104, 0.08400800824165344, 0.18473297357559204, 0.1363469660282135, -0.021599913015961647, -0.15502986311912537, 0.028037359938025475, -0.05864139646291733, -0.07465913146734238, -0.24884703755378723, -0.005743387155234814, -0.019903644919395447, -0.005537406541407108, -0.05742618814110756, -0.05224517360329628, 0.008402010425925255, -0.08550485968589783, 0.03846239298582077, 0.20844608545303345, -0.15113262832164764, 0.032256118953228, 0.04643477499485016, 0.08741189539432526, 0.13835209608078003, -0.23316234350204468, -0.021439606323838234, 0.05680103227496147], "changes": {"1wk": -14.221364501750275}}, {"text": "After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win PharmaVoice, an Industry Dive publication \u00b7 Pharma Voice \u00b7 Industry Dive Michael Gibney Thu, Jan 9, 2025, 9:44 AM 8 min de lecture Dans cet article: CADL +1.13% This story was originally published on PharmaVoice . To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter . Welcome to today\u2019s Biotech Spotlight, a series featuring companies creating breakthrough technologies and products. Today, we\u2019re looking at Candel Therapeutics, a company that recently welcomed a phase 3 win in prostate cancer with a viral immunotherapy approach following a restructuring of the company earlier last year. This time last year, Candel Therapeutics was burning at both ends. Now, despite tough decisions, the cancer immunotherapy company is celebrating a major win. For a clinical-stage biotech, navigating the treacherous market of the last few years is a testament to perseverance and resilience, as well as a belief in the fundamental science behind that work. Candel emerged from that harrowing landscape \u2014 through layoffs and other sacrifices \u2014 with late-stage clinical data that holds promise in the tricky area of prostate cancer, shedding light on a new approach in immuno-oncology. Candel\u2019s CEO, Dr. Paul Peter Tak, former chief immunology officer and global head of development at GSK, cut half of the company\u2019s workforce near the end of 2023 to make room for clinical costs, while also shedding manufacturing expenses to stretch its cash runway into the end of last year. \u201cIt\u2019s a very painful decision to let great people go \u2014 but I think that was the right decision,\u201d Tak said. \u201cFrom a business perspective, we were in survival mode.\u201d The strategy kept the company going in the runup to a December readout of positive phase 3 results for its lead viral immunotherapy candidate CAN-2409 in prostate cancer, reaching the primary endpoint of disease-free survival. The prospective drug is an off-the-shelf virus that delivers a type of herpes simplex gene to induce an immune response along with radiation therapy. Because Candel had a special protocol assessment agreement with the FDA, the prostate trial could serve as registrational for regulatory approval, and Tak said the company is aiming for a fourth-quarter 2026 submission to the agency. The biotech is also using similar therapeutic approaches for earlier-stage candidates in diseases like non-small cell lung cancer, pancreatic cancer and high-grade glioma. \"Viruses are very good at delivering genes to cells \u2014 that\u2019s what they do for a living.\" Dr. Paul Peter Tak CEO, Candel Therapeutics Candel saw its stock soar 200% on news of the trial success and shortly thereafter closed a public offering worth $92 million . The share price is almost 500% higher than it was a year ago, when the company was almost delisted from the Nasdaq stock exchange, Tak said. Lire la suite Here, Tak discusses Candel\u2019s unique approach to immunotherapy, CAN-2409\u2019s runaway success in the clinic that could land it a coveted spot in the treatment landscape, other candidates in its immuno-oncology pipeline and, of course, the hand-wringing process of making cuts to reprioritize that science. This interview has been edited for brevity and style. PHARMAVOICE: Using viruses to stimulate an immune response against a tumor, how does your platform stand apart from others in the immuno-oncology field? DR. PAUL PETER TAK: It\u2019s actually completely unique, which also leads to misunderstanding. CAN-2409 is a platform in itself, a pipeline in a product that we call a viral immunotherapy. Often people think it\u2019s an oncolytic virus, but it\u2019s not \u2014 it\u2019s an approach combining CAN-2409 delivered into a tumor with a small molecule tablet called valocyclovir [often used to treat herpes virus infections] that\u2019s taken for two weeks. Together that leads to in situ vaccination against the patient\u2019s own tumor as well as uninjected metastases. It\u2019s a vaccination approach against the whole variety of cancer antigens that are released in the tumor microenvironment. The virus is used basically for in vivo gene therapy. Viruses are very good at delivering genes to cells \u2014 that\u2019s what they do for a living. Similar to what\u2019s done in gene therapy, we deliver the herpes simplex virus thymidine kinase gene that leads to expression in the tumor. So then, when you give valocyclovir, it activates for a very strong inflammatory signal to the tumor microenvironment. In other words, you create the optimal conditions to vaccinate the patient against the patient\u2019s own variety of cancer antigens. That leads to an immune cell response that\u2019s largely mediated by CD8-positive tumor infiltrating lymphocytes that circulate throughout the body, and they will ultimately be the medicine against the tumor. A huge wave of checkpoint inhibitors made a really big difference in oncology in the last decade. What does the next wave look like? We are actually talking about the next wave now. When you think about the immune checkpoint inhibitors, which has been a major breakthrough for about a third of patients, you see durable responses and even cures. It\u2019s a paradigm shift. That\u2019s why the Nobel Prize was awarded to, among others, Jim Allison, who is on our research advisory board. But this leads to a non-specific activation of the immune response, and it doesn\u2019t work in all patients. CAN-2409 is an off-the-shelf product that leads to an individualized response. This is an example of a cutting-edge new frontier in immunotherapy. We also see the success of some other companies in different indications with slightly different approaches, like Replimune, CG Oncology and J&J, which moved into this field quite significantly with their viral immunotherapy. In fact we\u2019re working with [leading immunologist] Dr. Carl June to develop viral immunotherapies that may help bring his CAR-T cells into solid tumors like pancreatic cancer so we can convert non-responders to immune checkpoint inhibitors into responders, as we\u2019ve shown in non-small cell lung cancer. This is one example of the new frontier in immunotherapy. Tell me your perspective on the recent results for CAN-2409 and the primary endpoint of disease-free survival. This is a unique study because everybody else is focused on late-stage disease, but there\u2019s a big unmet need in early localized disease. It\u2019s not necessary to prolong life in terms of overall survival. Prostate cancer is the second most common cause of cancer after all the skin cancers grouped together, and it\u2019s not a problem that has been solved because the currently available treatments are associated with significant side effects and complications. So we wanted to increase the probability that patients would be disease-free over time so they would not need additional procedures associated with loss of quality of life. We wanted to show that there was no evidence whatsoever of any cancer cells in these patients \u2014 it was a very high hurdle, but we achieved it quite convincingly. This is a curative intent focusing on disease-free survival, which means there will be an immediate benefit in terms of quality of life because the patients don\u2019t need other treatments. Can you talk about what went into the decision to restructure the company earlier last year with cuts to both the workforce and manufacturing? Let\u2019s start with the priorities. We applied filters to the program, including the scientific rationale, the medical unmet need, the feasibility, the regulatory pathway and the market opportunity. We only focused on opportunities that are potential blockbusters. So you need to make choices \u2014 we\u2019ve always tried to keep the company very lean and work in a very cost-effective way. We did five clinical trials last year, and at some point we needed to make a decision about raising money at potentially unfavorable terms in a very difficult biotech market last year, one of the most difficult times in biotech history. We wanted to get in the most cost-effective way to the value-creating inflection points, and then you can raise money based on much more favorable terms. The phase 3 probability of success is, on average, about 35%. I did not feel comfortable making huge investments in manufacturing at risk before I had seen the data. I would have made the same decision when I was at GSK. We\u2019ve seen many other companies that fell over because they made big investments in manufacturing that were premature. The phase 3 program could have been negative, and then we would have spent tens of millions of dollars that we could have spent on other programs. I try to be very systematic about our decision trees. Now that it\u2019s positive, we want to go as fast as possible, but manufacturing always takes time. If we had invested a year ago at risk, we would be further ahead, but that\u2019s a decision we made with our eyes wide open, and I don\u2019t regret it at all. What does your cash runway look like now? We are in a very good position at the moment with the money we\u2019ve raised and other catalysts coming up even in this quarter. We expect overall survival data and biomarker data in non-small cell lung cancer and pancreatic cancer, and we will read out of the phase 1b clinical trial in high-grade glioma later this year \u2014 and that gives us additional opportunities to raise money. We\u2019ve not yet finalized our strategy with the board with all these events happening just a few weeks ago. At this moment we are in a very good spot. Are you looking forward to a busy J.P. Morgan healthcare conference next week with this data in hand? That could put some deals on the table. I\u2019ve always said that we will be open to the right strategic opportunity, but at the same time, we are not desperate and we will only do a deal that\u2019s good for patients and good for all stakeholders. Obviously, there\u2019s a lot of interest in the company, and we will continue to engage, but strategically, I\u2019m not interested in building a huge commercial organization myself and thereby cannibalizing the unique R&D capability we created. Having been a Big Pharma leader myself, I know that pharma companies are really good at getting this to as many patients as possible and extracting the value, but we will take our time to get to the right strategic deal and keep all options open, including going all the way ourselves. Recommended Reading Merck and Moderna\u2019s cancer vaccine snags a clinical win in a field decades old Afficher les commentaires CGU et Politique de confidentialit\u00e9 Privacy Dashboard Articles recommand\u00e9s", "symbol": "CADL", "date": "2025-01-09T06:44:44+00:00", "sentiment": {"score": 0.4696182906627655, "confidence": 0.6620535850524902, "probabilities": {"positive": 0.6620535850524902, "negative": 0.19243529438972473, "neutral": 0.1455111801624298}}, "embedding": [-0.20409627258777618, -0.046230748295784, -0.058296315371990204, -0.15027664601802826, 0.008662468753755093, -0.035453908145427704, 0.001307005062699318, 0.16285058856010437, 0.06966766715049744, 0.07495321333408356, -0.12197880446910858, 0.17726247012615204, 0.09078985452651978, 0.11281049251556396, -0.07722586393356323, 0.01736847683787346, 0.01167537271976471, 0.01774938963353634, -0.04193701222538948, 0.07586224377155304, 0.0016125142574310303, -0.03504972159862518, 0.020969942212104797, 0.08811923861503601, -0.07636085152626038, -0.01033807173371315, -0.05319243296980858, -0.00863967090845108, -0.1680445373058319, -0.1359778642654419, -0.0081018703058362, 0.03590830788016319, -0.024330303072929382, -0.04818880930542946, 0.021615613251924515, 0.03385873883962631, -0.1154613271355629, 0.08463653922080994, -0.047232165932655334, -0.05590369552373886, 0.021711241453886032, -0.11460036784410477, -0.12832465767860413, 0.09104567021131516, 0.08255045115947723, -0.18603432178497314, -0.042315490543842316, -0.09854605048894882, 0.0712684690952301, 0.06630305200815201, -0.12085190415382385, -0.13630735874176025, 0.05301491916179657, 0.0005703018978238106, -0.017312662675976753, -0.030765611678361893, -0.11290432512760162, 0.023293182253837585, 0.0010841302573680878, 0.057787612080574036, 0.07734687626361847, -0.11211471259593964, -0.03880424052476883, -0.00950708333402872, 0.17690923810005188, -0.054742805659770966, -0.049328211694955826, 0.03434233367443085, -0.06948808580636978, 0.005398178473114967, 0.13592272996902466, -0.042099013924598694, -0.06525293737649918, 0.09601877629756927, 0.06599995493888855, 0.05288628116250038, 0.14247941970825195, 0.17187324166297913, 0.12851862609386444, -0.06748788058757782, 0.1152859628200531, -0.10458877682685852, 0.003894568420946598, 0.03821606934070587, -0.18151447176933289, -0.09328349679708481, -0.08667604625225067, 0.12575176358222961, 0.13698413968086243, -0.028067443519830704, 0.016874980181455612, 0.0032484717667102814, 0.025662127882242203, 0.057692259550094604, 0.02099071815609932, 0.012492706999182701, -0.02124452404677868, -0.006842979229986668, 0.037374675273895264, 0.019964799284934998, -0.0024762083776295185, -0.04465313255786896, -0.01213807798922062, -0.15343207120895386, -0.07401604950428009, -0.12870502471923828, -0.05328486114740372, -0.08822232484817505, 0.09218902140855789, 0.07699037343263626, -0.07310168445110321, -0.021330615505576134, 0.03314059227705002, 0.009959747083485126, -0.03003326617181301, 0.18728339672088623, -0.11761301755905151, -0.049895428121089935, 0.09247472882270813, -0.08841903507709503, 0.04019616171717644, 0.024854078888893127, 0.006063668057322502, -0.027290677651762962, 0.01235139649361372, 0.18375353515148163, 0.038902267813682556, 7.79746618671099e-33, 0.032152287662029266, 0.09272392094135284, 0.0573614239692688, 0.11699703335762024, 0.011345366016030312, 0.03220124542713165, 0.17442473769187927, -0.0709988921880722, -0.12434689700603485, -0.18060961365699768, -0.03762378916144371, 0.05139463394880295, -0.006417746655642986, 0.011662263423204422, -0.1117747575044632, -0.1266198605298996, -0.02174263447523117, 0.08730381727218628, -0.05849234759807587, 0.011691473424434662, 0.05948152765631676, 0.06493805348873138, -0.03422120213508606, 0.03263898938894272, -0.02467772178351879, 0.06396757811307907, -0.07238590717315674, 0.09845487773418427, 0.0541052520275116, 0.01852121762931347, -0.0447964072227478, 0.1526017189025879, -0.015636686235666275, -0.03905542194843292, -0.01607554219663143, -0.0493052676320076, 0.012265561148524284, -0.1133478432893753, 0.12532316148281097, 0.039212994277477264, -0.003941136412322521, 0.05937417596578598, -0.03910382091999054, -0.11248168349266052, 0.07275182753801346, 0.0019177207723259926, -0.050010330975055695, -0.02634379453957081, -0.11368747055530548, 0.061923857778310776, 0.00925455056130886, 0.06454704701900482, -0.002089396119117737, -0.07376442849636078, -0.023596756160259247, 0.06578825414180756, -0.10377306491136551, -0.005787207745015621, 0.10322645306587219, 0.1078648567199707, 0.024779098108410835, 0.0829257071018219, 0.028223341330885887, 0.08586684614419937, -0.11609698832035065, 0.004268348217010498, -0.0785885900259018, -0.017422186210751534, -0.05053328722715378, 0.23092399537563324, -0.053169816732406616, -0.003022216260433197, 0.03394363820552826, -0.06543047726154327, 0.07756254076957703, -0.05359281599521637, -0.0534786581993103, 0.10262664407491684, -0.07820434868335724, 0.02266721799969673, -0.027370311319828033, 0.07625767588615417, -0.1726313829421997, 0.1121634840965271, -0.030977051705121994, -0.03715813159942627, 0.07775257527828217, -0.04989144578576088, -0.14895029366016388, 0.007375284098088741, -0.0055779628455638885, 0.004865443333983421, 0.034149620682001114, 0.17176568508148193, 0.04114607721567154, -1.0192000341897807e-32, 0.022457847371697426, -0.06414379179477692, 0.04922329634428024, -0.018867673352360725, 0.1137065440416336, 0.03184512257575989, 0.0922226831316948, -0.04068532586097717, 0.08554798364639282, 0.014773715287446976, 0.04645479843020439, -0.02411871775984764, 0.0055604251101613045, -0.03855419531464577, -0.16449667513370514, -0.016070712357759476, 0.06806345283985138, -0.07271881401538849, -0.19561782479286194, -0.03480356186628342, 0.06765192002058029, 0.18533211946487427, -0.21293583512306213, 0.13287252187728882, -0.12558187544345856, 0.09335577487945557, 0.006317492574453354, 0.04234766215085983, 0.04674771800637245, -0.00991989765316248, -0.025125227868556976, 0.035426270216703415, -0.19658273458480835, 0.032135266810655594, 0.029273824766278267, 0.0367782786488533, 0.041751209646463394, -0.14062923192977905, 0.04370046406984329, -0.15905268490314484, 0.09711149334907532, 0.00655791349709034, -0.1141766756772995, 0.02751798927783966, 0.07314905524253845, 0.030206765979528427, 0.09036169201135635, -0.01072077639400959, 0.23155231773853302, 0.052859291434288025, -0.024539748206734657, -0.10062617063522339, 0.06004447117447853, 0.0319010466337204, -0.06545250117778778, -0.10913857817649841, 0.05500607565045357, -0.03468119353055954, -0.06890583783388138, 0.01771429367363453, -0.025974011048674583, 0.029780756682157516, 0.07568952441215515, -0.03604021295905113, 0.024403724819421768, 0.10476592183113098, 0.07582317292690277, -0.086381696164608, 0.010303220711648464, -0.04809188097715378, -0.08701276034116745, -0.01222303882241249, -0.029877936467528343, -0.018099531531333923, 0.05606498569250107, 0.1311366856098175, -0.06315532326698303, -0.1064043715596199, -0.18457099795341492, -0.07312940806150436, -0.025289926677942276, -0.11025077849626541, -0.013579954393208027, -0.0359359048306942, 0.20859530568122864, 0.09891416877508163, -0.0006573619320988655, -0.026492437347769737, 0.04361771419644356, 0.006972028408199549, -0.11308404803276062, -0.09645234048366547, -0.084768146276474, 0.08505963534116745, -0.014755286276340485, -1.0058876398488792e-07, 0.08622807264328003, -0.12796613574028015, -0.03886505961418152, -0.11308850347995758, -0.006523672491312027, -0.04095496982336044, -0.06090709939599037, 0.03670183941721916, 0.15400511026382446, 0.12760047614574432, 0.08505833148956299, 0.08194684982299805, -0.07437940686941147, 0.09999311715364456, -0.024837050586938858, 0.0996582955121994, -0.0009388374164700508, 0.026925763115286827, -0.05894068256020546, -0.07038430869579315, -0.14243118464946747, -0.013469049707055092, -0.0514092817902565, -0.01704254373908043, 0.048778120428323746, -0.013432135805487633, -0.039556413888931274, 0.03229275345802307, 0.030984312295913696, -0.07932870090007782, -0.012867521494626999, -0.07751453667879105, -0.007927700877189636, 0.14722727239131927, -0.048032596707344055, -0.1062934398651123, 0.15863007307052612, 0.10719522088766098, 0.014249209314584732, 0.04789046198129654, 0.03988826647400856, 0.054860688745975494, -0.08962638676166534, 0.013779284432530403, -0.1284480094909668, -0.0935070812702179, -0.1427595317363739, -0.006601936183869839, -0.06480535864830017, -0.023673880845308304, -0.03232754021883011, -0.05402563512325287, 0.012394899502396584, -0.0975198969244957, -0.02801898494362831, 0.10619446635246277, -0.09018020331859589, -0.030152255669236183, -0.010538384318351746, 0.033351123332977295, 0.10573050379753113, -0.21323639154434204, 0.11339394748210907, 0.11223745346069336], "changes": {"1wk": -2.200492646215289}}, {"text": "CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal Zacks Equity Research Thu, Dec 12, 2024, 6:31 PM 5 min read In This Article: CADL +1.13% PFE -1.21% Shares of Candel Therapeutics CADL surged 68.1% on Wednesday after the company reported superior efficacy of CAN-2409, an investigational adenovirus immunotherapy candidate, compared to standard of care (SOC) radiation therapy alone in a late-stage study to treat prostate cancer. The phase III study enrolled intermediate-to-high-risk, localized prostate cancer patients who either received the combination therapy of CAN-2409+prodrug (valacyclovir)+SOC or SOC alone. The study met its primary endpoint, demonstrating statistically significant improvement in disease-free survival (DFS) in patients\u00a0receiving the combo therapy compared to SOC alone. Per Candel, in the United States, over 100,000 men are diagnosed annually with localized prostate cancer, with more than 50,000 receiving radiotherapy. Despite being the second leading cause of cancer death among men, there has been no major advancement in treatment for localized, non-metastatic cases in over 20 years. The addressable market for CAN-2409 in this area is valued at over $10 billion, representing a significant opportunity for Candel. In the past three months, shares of Candel have gained 10.6% against the industry\u2019s 8.9% fall. Zacks Investment Research Image Source: Zacks Investment Research More on CADL\u2019s Prostate Cancer Study Data Candel reported that prostate cancer patients treated with the CAN-2409 combo therapy achieved a 14.5% relative improvement in DFS compared to the placebo control arm. A subsequent analysis of prostate-specific outcomes in the phase III study revealed a highly significant effect of CAN-2409 on prostate cancer-free survival. The treatment arm demonstrated a substantial increase in the proportion of patients achieving a prostate-specific antigen nadir, associated with better cancer control outcomes, compared to the placebo control arm (67.1% vs. 58.6%, respectively). Additionally, treatment with the combo therapy resulted in 80.4% pathological complete responses in the 2-year post-treatment biopsies compared to 63.6% observed in the control arm. In the phase III prostate cancer study, CAN-2409 was overall well tolerated and demonstrated a safety profile consistent with previous studies. No new safety signals were identified. Adverse events related to treatment with the candidate were mostly mild to moderate in severity. In the same press release, Candel reported top-line data from its phase II study evaluating CAN-2409 as a monotherapy in patients with low-to-intermediate risk localized prostate cancer undergoing active surveillance. Per the data readout, treatment with the candidate demonstrated numerical improvement in time to radical treatment and the percentage of patients achieving negative (prostate cancer-free) biopsies at 1-year post treatment. However, such improvements did not reach statistical significance. Story Continues CADL\u2019s Next Steps in CAN-2409 Development Based on the encouraging phase III and phase II study data, Candel plans to initiate discussions with the FDA regarding the regulatory pathway for CAN-2409 in intermediate-to-high-risk localized prostate cancer.\u00a0Detailed results from both studies will be presented at a later medical conference. Please note that the phase III study of CAN-2409 for the prostate cancer indication was conducted under a Special Protocol Assessment with the FDA. This means the study's safety and efficacy data can support a regulatory filing for the candidate for the same indication in the United States. Subject to approval, Candel believes that CAN-2409 has the potential to transform the treatment paradigm in prostate cancer. It will offer patients with localized disease an effective treatment option that may reduce the risk of disease recurrence. Apart from the prostate cancer indication, Candel is also currently evaluating CAN-2409 in separate mid-stage studies for pancreatic and lung cancer indications. The company\u2019s clinical pipeline comprises another candidate, CAN-3110, an HSV-1-based immunotherapy candidate, which is being evaluated for a brain cancer indication in an early-stage study. Candel Therapeutics, Inc. Price and Consensus Candel Therapeutics, Inc. Price and Consensus Candel Therapeutics, Inc. price-consensus-chart | Candel Therapeutics, Inc. Quote CADL\u2019s Zacks Rank and Stocks to Consider Candel currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the drug/biotech industry are Bristol Myers BMY, Pfizer PFE and Gilead Sciences GILD, each carrying a Zacks Rank #2 (Buy) at present.\u00a0You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here . Over the past 60 days, estimates for Bristol Myers\u2019 2024 earnings have increased from 75 cents to 91 cents per share. Estimates for 2025 earnings per share have increased from $7.05 to $7.19 in the same time frame. BMY shares have gained 15.3% in the past three months. Bristol Myers\u2019 earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.54%. In the past 60 days, estimates for Pfizer\u2019s 2024 earnings have risen from $2.66 to $2.92 per share. Estimates for 2025 earnings per share have increased from $2.86 to $2.94 in the same time frame. PFE shares have lost 13.8% in the past three months. Pfizer\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%. In the past 60 days, estimates for Gilead Sciences\u2019 2024 earnings have risen from $3.78 to $4.29 per share. Estimates for 2025 earnings per share have increased from $7.24 to $7.38 in the same time frame. GILD shares have risen 11.6% in the past three months. Gilead Sciences\u2019 earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Candel Therapeutics, Inc. (CADL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CADL", "date": "2024-12-12T15:31:00+00:00", "sentiment": {"score": 0.9399216528981924, "confidence": 0.9559987783432007, "probabilities": {"positive": 0.9559987783432007, "negative": 0.016077125445008278, "neutral": 0.027924178168177605}}, "embedding": [-0.03522423654794693, -0.07469652593135834, -0.14924664795398712, -0.14427125453948975, -0.031182825565338135, -0.08788321912288666, -0.010006453841924667, 0.24756065011024475, 0.20526036620140076, 0.10168074071407318, -0.1112467348575592, 0.2342294305562973, 0.10599111765623093, 0.09849105775356293, 0.049852319061756134, -0.02039562538266182, 0.1523708701133728, -0.06874081492424011, -0.12262028455734253, 0.11783255636692047, -0.016562888398766518, -0.05805351585149765, 0.07555639743804932, 0.06736978888511658, -0.05026228725910187, -0.12750054895877838, -0.14039313793182373, 0.04126805067062378, -0.13569685816764832, -0.04792465269565582, 0.10303004086017609, 0.07433095574378967, -0.04897039383649826, -0.05307731777429581, -0.008954763412475586, -0.02466161735355854, -0.15285415947437286, 0.11622108519077301, -0.12958616018295288, 0.02132987417280674, 0.00013949465937912464, -0.04259376972913742, -0.0901644378900528, 0.07833202928304672, -0.011362619698047638, -0.18772663176059723, -0.12629543244838715, -0.023892322555184364, 0.11147202551364899, 0.14658024907112122, -0.047998182475566864, -0.031763046979904175, 0.04560151696205139, 0.030899977311491966, 0.002174844965338707, -0.15463529527187347, -0.06788409501314163, 0.027589280158281326, -0.039995551109313965, 0.10092432796955109, -0.008748751133680344, -0.15609881281852722, -0.03492577373981476, 0.005571380257606506, 0.10896196216344833, 0.026121944189071655, -0.08937159925699234, -0.012463124468922615, -0.01788797602057457, 0.017201991751790047, 0.13941778242588043, -0.041510049253702164, -0.056943245232105255, 0.049916595220565796, -0.05767565965652466, -0.041327767074108124, 0.1592726707458496, 0.1973145455121994, 0.11492305994033813, -0.11420966684818268, 0.03016814962029457, 0.03196672350168228, 0.018835941329598427, -0.014771978370845318, -0.08510535210371017, -0.04094986617565155, 0.010607742704451084, 0.1859438419342041, 0.06430727243423462, 0.0511203333735466, 0.09939426183700562, 0.06530674546957016, 0.03234487771987915, 0.0011359928175807, 0.014353012666106224, -0.030706167221069336, -0.01857268065214157, -0.08913494646549225, -0.023933297023177147, -0.015610095113515854, 0.06231217831373215, -0.09219875931739807, -0.09360238909721375, -0.15006688237190247, -0.13526496291160583, -0.13076862692832947, -0.09373509883880615, 0.0008475044742226601, 0.005156341940164566, 0.09518682956695557, -0.0060675791464746, -0.061217933893203735, 0.03157835081219673, 0.05511561036109924, -0.08216459304094315, 0.13727252185344696, -0.07047050446271896, -0.03195061534643173, 0.11288312077522278, -0.11659452319145203, -0.004161173477768898, -0.0205082967877388, 0.1374550461769104, 0.021577464416623116, 0.01379656046628952, 0.160633385181427, 0.01588134467601776, 1.0153690981004509e-32, 0.0377645380795002, 0.016314828768372536, 0.032560084015131, -0.02992752566933632, 0.00154845230281353, -0.024394825100898743, 0.19253483414649963, 0.02019747532904148, -0.08074724674224854, -0.18004512786865234, 0.10645909607410431, 0.029420608654618263, 0.09638398140668869, 0.035213276743888855, -0.13805599510669708, -0.04071241617202759, -0.009107496589422226, 0.07046845555305481, -0.19466912746429443, -0.0005949335172772408, 0.04656757041811943, 0.05905121937394142, 0.018987368792295456, 0.06934843212366104, -0.05781412869691849, 0.02011726051568985, -0.11294923722743988, 0.10929961502552032, 0.010100272484123707, 0.019667930901050568, -0.04099187254905701, 0.03748633340001106, 0.01244313269853592, -0.07040340453386307, 0.0028034113347530365, -0.03939686343073845, 0.004354416858404875, -0.019127946346998215, 0.13369090855121613, 0.05129307135939598, -0.03293195739388466, -0.037152133882045746, 0.040249329060316086, -0.07286939024925232, 0.013265926390886307, -0.09131336212158203, -0.02839987725019455, 0.0009551611728966236, -0.20673838257789612, -0.002474788576364517, -0.09747249633073807, 0.045184426009655, -0.03976883739233017, 0.0006814999505877495, -0.0815405547618866, 0.011468694545328617, -0.10352011024951935, 0.04871707782149315, 0.03274451941251755, 0.09571798145771027, 0.045078832656145096, 0.05752333998680115, 0.10827021300792694, 0.028769753873348236, -0.15805357694625854, 0.029983552172780037, -0.014775505289435387, -0.06058802828192711, -0.05159524828195572, 0.2093774676322937, -0.050173528492450714, 0.13613268733024597, 0.08875013887882233, -6.223376840353012e-05, 0.054203107953071594, -0.07614997029304504, 0.03299512714147568, 0.15901565551757812, -0.05723774433135986, 0.16004708409309387, -0.14138443768024445, -0.04643409326672554, -0.1779567301273346, 0.12311961501836777, -0.018519653007388115, 0.016405094414949417, 0.027825940400362015, -0.0019500385969877243, -0.19785436987876892, -0.024521511048078537, 0.02574019506573677, -0.026737064123153687, 0.031177563592791557, 0.09974168241024017, 0.09911826252937317, -1.175488840692518e-32, -0.027353374287486076, -0.020544372498989105, 0.15947523713111877, -0.048971064388751984, 0.07130205631256104, 0.005150971002876759, 0.01933274418115616, -0.1713975965976715, 0.08100216090679169, -0.06227710843086243, 0.03310979902744293, 0.11223244667053223, -0.004343475680798292, -0.06571664661169052, -0.15794804692268372, -0.03596394881606102, -0.11241693049669266, -0.10430611670017242, -0.1146046370267868, -0.06471885740756989, 0.07350225746631622, 0.17200344800949097, -0.0214238278567791, 0.11522181332111359, -0.15760192275047302, 0.020937547087669373, 0.0003493818221613765, 0.00861721858382225, 0.11272138357162476, 0.01763235777616501, 0.07687550783157349, 0.09730247408151627, -0.22068868577480316, 0.03414176404476166, 0.019921790808439255, -0.013780130073428154, 0.06204976886510849, -0.10321860015392303, -0.01351376436650753, -0.06231303885579109, 0.011256469413638115, 0.13835409283638, -0.028252404183149338, -0.03571214899420738, 0.07442271709442139, 0.046870164573192596, 0.084761843085289, -0.00011798553168773651, 0.26844900846481323, 0.07433274388313293, -0.01570935733616352, -0.03178226575255394, 0.007780726999044418, 0.1319941282272339, -0.046468935906887054, -0.15378034114837646, 0.06237618252635002, -0.004959167912602425, -0.22632312774658203, -0.028950095176696777, -0.032020874321460724, 0.04552433639764786, 0.04568956792354584, -0.016340026631951332, 0.008909281343221664, 0.07780539244413376, -0.02911336161196232, -0.03673937916755676, 0.08125942945480347, -0.0794089064002037, -0.04125288873910904, -0.1044946163892746, -0.0014247894287109375, -0.06928332149982452, -0.019313884899020195, 0.19500994682312012, 0.0900195986032486, -0.07598788291215897, -0.09636086225509644, -0.061231937259435654, -0.15818056464195251, -0.08408178389072418, -0.0992356538772583, -0.025120163336396217, 0.05948846787214279, 0.19638948142528534, -0.00813690572977066, -0.062190935015678406, -0.05121682584285736, 0.0605628676712513, -0.13511177897453308, -0.058963075280189514, -0.023689642548561096, -0.009613646194338799, -0.09230111539363861, -1.0057372179517188e-07, 0.056444186717271805, -0.07303541898727417, -0.0011452515609562397, -0.04823843762278557, -0.029721200466156006, 0.005229550879448652, -0.03286862373352051, -0.0213494710624218, 0.04459630697965622, 0.10751873254776001, 0.10788977891206741, 0.10448601841926575, -0.13813108205795288, -0.026335015892982483, -0.09659650921821594, -0.002066832035779953, 0.046719904989004135, 0.039595335721969604, 0.007298467215150595, -0.08044786751270294, -0.09339611232280731, -0.16930487751960754, 0.013849407434463501, -0.05049226060509682, -0.04000610485672951, 0.0842820256948471, 0.044556908309459686, 0.05043036490678787, 0.07274866104125977, -0.07841955870389938, 0.03549715131521225, -0.19119107723236084, 0.021315693855285645, 0.07600114494562149, 0.1635454297065735, -0.04466601833701134, 0.04274146258831024, 0.10008533298969269, 0.05396163463592529, 0.17556089162826538, 0.09472264349460602, -0.015108074061572552, -0.06616488099098206, 0.07286722213029861, -0.10721322894096375, -0.0002858131192624569, -0.14321549236774445, -0.06614474207162857, -0.06571830809116364, -0.015454467386007309, 0.03289451450109482, 0.01023513451218605, 0.0014591091312468052, -0.07412867248058319, -0.051212213933467865, 0.24238789081573486, -0.04374516010284424, -0.10749316215515137, 0.07221369445323944, 0.07364913076162338, 0.09986235201358795, -0.1632433384656906, 0.010758440010249615, 0.04486709088087082], "changes": {"1wk": 1.6326514724293246, "1mo": -16.530610755402492}}, {"text": "PREMIUM Candel Therapeutics Closes Securities Offering to Raise $92 Million MT Newswires Tue, Dec 17, 2024, 1:55 AM 1 min read In This Article: CADL +1.13% Candel Therapeutics (CADL) closed an offering of 12 million shares at $6 apiece and prefunded warran PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CADL", "date": "2024-12-16T22:55:10+00:00", "sentiment": {"score": 0.04157084319740534, "confidence": 0.05503932759165764, "probabilities": {"positive": 0.05503932759165764, "negative": 0.0134684843942523, "neutral": 0.9314922094345093}}, "embedding": [-0.1379621922969818, -0.06561660021543503, -0.0818706750869751, 0.12349008768796921, -0.06687673926353455, 0.0018227342516183853, -0.01480893138796091, 0.10352925211191177, 0.13597483932971954, 0.14021563529968262, 0.051983632147312164, 0.11460188776254654, 0.043098386377096176, 0.07470835745334625, -0.03894233703613281, 0.037021346390247345, 0.02527499757707119, -0.037088558077812195, -0.09742383658885956, 0.15712906420230865, -0.08208052814006805, 0.03534736856818199, -0.1295149326324463, 0.038039106875658035, 0.08615874499082565, -0.10628291964530945, -0.08310898393392563, -0.0895395427942276, -0.035505685955286026, -0.07243963330984116, -0.03547045588493347, -0.05011211708188057, -0.11416172236204147, -0.072329081594944, 0.17888079583644867, 0.03305946663022041, -0.09890944510698318, -0.04933854565024376, -0.11542730778455734, -0.020815052092075348, 0.00048821355449035764, -0.10042698681354523, -0.21933995187282562, 0.03641396015882492, -0.07380929589271545, -0.14742611348628998, -0.049782007932662964, 0.11511627584695816, 0.14551785588264465, 0.15745849907398224, -0.09647518396377563, -0.09471724927425385, 0.05049576982855797, -0.13369210064411163, 0.0007817161967977881, -0.08125602453947067, -0.15925022959709167, -0.08241347968578339, -0.020300598815083504, 0.030765404924750328, 0.0414421409368515, -0.055358778685331345, -0.13372521102428436, -0.016814099624753, -0.03077363781630993, 0.008121204562485218, 0.03802185133099556, 0.14016588032245636, 0.057552311569452286, -0.19645066559314728, 0.15526480972766876, 0.020971208810806274, 0.1344497799873352, 0.06908397376537323, 0.013183626346290112, 0.1244872435927391, 0.23794318735599518, -0.03485593572258949, 0.07757728546857834, -0.1581019163131714, 0.03530670329928398, 0.01605226658284664, -0.09086771309375763, -0.04771943390369415, -0.01709350198507309, 0.04345911741256714, 0.07166182994842529, 0.08354686945676804, 0.20329226553440094, -0.06370438635349274, 0.1903909593820572, -0.014536595903337002, -0.09300519526004791, 0.03475765138864517, -0.2754824161529541, -0.02870595082640648, -0.08257347345352173, -0.04585513845086098, -0.12530651688575745, 0.06515853106975555, 0.10151182115077972, -0.002071766648441553, -0.0081272441893816, -0.14577558636665344, -0.09934911876916885, -0.09861522167921066, 0.024235347285866737, 0.11630936712026596, -0.024393415078520775, -0.05327986925840378, -0.0870879590511322, 0.023065542802214622, -0.0007672666106373072, -0.08353346586227417, -0.09292907267808914, 0.1684628129005432, -0.11193185299634933, -0.07487457245588303, 0.10078365355730057, -0.0537702739238739, 0.02222001552581787, 0.1488959789276123, -0.03494785726070404, -0.008511009626090527, -0.11465296149253845, 0.0011369679123163223, -0.03123076818883419, 1.320841582439174e-32, -0.06618721783161163, 0.1108848974108696, -0.03806029260158539, 0.10195931047201157, 0.09078065305948257, -0.042991284281015396, 0.11844798177480698, -0.11401860415935516, -0.23978441953659058, -0.02410735934972763, -0.1274978369474411, 0.06648200750350952, -0.07472957670688629, 0.048371534794569016, -0.08553040027618408, -0.26404112577438354, 0.03585268557071686, 0.06782174855470657, 0.06739810854196548, 0.017007019370794296, 0.05617798492312431, 0.05664953589439392, 0.014862448908388615, 0.03306559473276138, -0.09725450724363327, 0.1666630357503891, 0.04693944752216339, -0.019593194127082825, 0.16862204670906067, 0.09526292234659195, -0.04359779879450798, 0.04757922887802124, 0.16511547565460205, -0.029603157192468643, 0.061485741287469864, 0.13194163143634796, 0.02267279289662838, -0.06599996984004974, 0.11582821607589722, -0.1721867173910141, 0.05852014198899269, 0.1187618300318718, -0.22873958945274353, -0.026355566456913948, -0.07399210333824158, 0.009594880044460297, -0.03407768905162811, 0.03527941182255745, -0.07689420133829117, -0.0989120602607727, -0.013373110443353653, 0.14146468043327332, -0.24501042068004608, -0.0011092344066128135, -0.1181410402059555, 0.007797729689627886, -0.07707393169403076, -0.06246156245470047, 0.14707233011722565, 0.056199971586465836, 0.11446106433868408, 0.12971536815166473, 0.08799527585506439, -0.007672413717955351, -0.19533029198646545, 0.11654423177242279, -0.04060627892613411, -0.04248708114027977, -0.14981681108474731, 0.1603669971227646, -0.03496331721544266, 0.051636941730976105, 0.07307832688093185, -0.02216571383178234, -0.007844878360629082, -0.008325495757162571, 0.02075354941189289, -0.009573542512953281, 0.2371186912059784, 0.1603095531463623, 0.13937939703464508, -0.07971595972776413, 0.05434900149703026, 0.15331360697746277, 0.056922245770692825, 0.05201830714941025, 0.06338118761777878, 0.1026996597647667, -0.16433365643024445, -0.021444855257868767, -0.02298165112733841, 0.04256347194314003, 0.01263418048620224, 0.043647319078445435, 0.07532154023647308, -1.5579887515099393e-32, -0.09811779856681824, 0.008257088251411915, 0.09016785025596619, -0.12124517560005188, -0.08234847337007523, -0.051108792424201965, -0.06831873953342438, 0.09495704621076584, 0.022259829565882683, 0.17806999385356903, 0.14371483027935028, 0.03912314400076866, -0.11631498485803604, 0.0989886075258255, -0.028744695708155632, -0.1266138255596161, 0.10435310751199722, -0.08448877185583115, -0.09418144822120667, -0.05224503204226494, -0.13815109431743622, 0.12407422810792923, -0.109097920358181, 0.19458353519439697, 0.15031854808330536, 0.07949100434780121, -0.07238742709159851, 0.1288479119539261, 0.07426932454109192, 0.12306971102952957, 0.06413039565086365, -0.08888040482997894, -0.17043423652648926, 0.11249522864818573, 0.07331109791994095, 0.01964065060019493, 0.20369429886341095, 0.014112909324467182, -0.014597507193684578, -0.09453663229942322, 0.15556246042251587, -0.09631805866956711, -0.04804883897304535, 0.05469365417957306, 0.03461792692542076, -0.03034904971718788, -0.032876964658498764, -0.15816248953342438, 0.2141639143228531, -0.01369866169989109, -0.08811972290277481, -0.07099312543869019, 0.14996939897537231, 0.12497985363006592, -0.10582929104566574, 0.028042342513799667, 0.13818305730819702, -0.08080492913722992, 0.05151185393333435, -0.17852970957756042, 0.01576373167335987, 0.14281021058559418, -0.16381755471229553, -0.02631179429590702, -0.017764631658792496, -0.02423783764243126, 0.027574388310313225, -0.1686059534549713, -0.08459912240505219, -0.15463034808635712, 0.09642713516950607, -0.0031599760986864567, 0.038617298007011414, -0.2172548472881317, -0.08950470387935638, 0.21631526947021484, -0.041034139692783356, -0.09277980029582977, -0.06374930590391159, -0.042287010699510574, 0.06231158971786499, -0.11509797722101212, 0.029711740091443062, -0.06306613236665726, 0.08725480735301971, 0.0005993631202727556, 0.11520436406135559, -0.012117967940866947, -0.07800538092851639, 0.15905240178108215, -0.2512499690055847, -0.1919626146554947, 0.00994445476680994, 0.04249616712331772, 0.0045210518874228, -1.0044750808901881e-07, -0.055674731731414795, -0.04375484958291054, -0.014971268363296986, -0.11029602587223053, -0.004843071568757296, -0.01901061274111271, -0.05107950419187546, 0.0920557826757431, 0.08443493396043777, 0.26132258772850037, 0.16669227182865143, 0.06830663979053497, -0.1805431991815567, 0.007802206557244062, -0.2268730103969574, -0.06114733964204788, -0.0747516006231308, 0.03867999091744423, 0.06239954009652138, -0.20147524774074554, -0.030181290581822395, 0.13895781338214874, 0.22509242594242096, -0.12824061512947083, 0.036152277141809464, -0.04811175540089607, 0.00188656325917691, 0.048565562814474106, -0.02562282793223858, -0.16725294291973114, 0.028694411739706993, -0.09024463593959808, -0.032422419637441635, 0.12929180264472961, 0.05032676085829735, 0.1558188945055008, -0.04658304527401924, 0.19735758006572723, -0.03641415387392044, 0.10049072653055191, -0.023949040099978447, -0.02630080282688141, 0.005099525675177574, 0.07527889311313629, 0.018493566662073135, -0.008474800735712051, -0.18274682760238647, -0.10015003383159637, 0.1417715698480606, -0.13564036786556244, 0.08357244729995728, -0.05795073136687279, 0.06893795728683472, -0.13361132144927979, -0.16878017783164978, 0.1728430539369583, -0.11009979248046875, 0.0918368324637413, -0.24749301373958588, 0.010751736350357533, -0.04145238175988197, -0.3512815833091736, -0.01825666055083275, 0.034636497497558594], "changes": {"1wk": 40.211207477921974, "1mo": 29.9756251389161}}, {"text": "PREMIUM Candel Therapeutics Prices $80 Million Public Offering MT Newswires Fri, Dec 13, 2024, 12:12 PM In This Article: CADL +1.13% Candel Therapeutics (CADL) said late Thursday it priced an underwritten public offering of 10 millio PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CADL", "date": "2024-12-13T09:12:38+00:00", "sentiment": {"score": 0.04861715901643038, "confidence": 0.06107103452086449, "probabilities": {"positive": 0.06107103452086449, "negative": 0.012453875504434109, "neutral": 0.9264750480651855}}, "embedding": [-0.18085719645023346, -0.035371333360672, -0.04624571651220322, 0.09400300681591034, 0.00865983497351408, -0.022234449163079262, -0.05241534858942032, 0.12687788903713226, 0.12640899419784546, 0.04595641419291496, 0.018999096006155014, 0.04030182212591171, 0.10842088609933853, 0.0785343199968338, -0.04082386568188667, -0.06904277205467224, 0.18421104550361633, -0.053006164729595184, -0.015301717445254326, 0.23123010993003845, -0.06078484281897545, 0.07387682795524597, -0.1410357654094696, 0.10239607840776443, 0.12303294241428375, -0.12114248424768448, -0.08126174658536911, -0.15833155810832977, -0.011221548542380333, -0.09365789592266083, -0.10463418066501617, 0.018296176567673683, -0.054538045078516006, -0.06193118169903755, 0.17794367671012878, -0.08694203197956085, -0.02716962620615959, -0.06458080559968948, -0.16683341562747955, -0.011358210816979408, 0.027183454483747482, -0.15917643904685974, -0.20427340269088745, -0.03401072323322296, -0.04864224046468735, -0.20310154557228088, 0.01453540101647377, 0.12126932293176651, 0.15801481902599335, 0.21763944625854492, -0.06558060646057129, -0.07591010630130768, 0.03483942523598671, -0.15493354201316833, -0.013128036633133888, -0.042386457324028015, -0.19198155403137207, -0.07780495285987854, -0.07677605748176575, 0.052807603031396866, -0.04659789055585861, -0.050538018345832825, -0.17743955552577972, 0.06601230800151825, -0.048313386738300323, 0.04340494051575661, 0.014274143613874912, 0.08127692341804504, 0.11558406800031662, -0.24872879683971405, 0.15422342717647552, -0.006222499068826437, 0.21048130095005035, 0.0223198514431715, 0.14906835556030273, 0.09522473067045212, 0.3211798369884491, 0.003984431736171246, 0.11664347350597382, -0.1782999336719513, 0.019757701084017754, -0.045514073222875595, 0.007350781466811895, -0.04242732375860214, 0.08455511182546616, -0.02757781185209751, 0.08162321150302887, 0.13887770473957062, 0.15545490384101868, -0.12730902433395386, 0.20419473946094513, -0.03545873984694481, -0.15592926740646362, 0.020512588322162628, -0.22643247246742249, 0.027492137625813484, -0.11342514306306839, -0.0354941263794899, -0.029030798003077507, -0.0022132040467113256, 0.05728766694664955, 0.0057465690188109875, 0.07030149549245834, -0.043014850467443466, -0.08136073499917984, -0.12942638993263245, 0.02382609248161316, 0.11121542006731033, 0.09400319308042526, 0.018023105338215828, -0.03617722913622856, -0.024704955518245697, 0.06299682706594467, -0.03970583155751228, -0.07743667811155319, 0.007133763749152422, -0.07172541320323944, -0.1739170253276825, 0.08851829916238785, -0.06589557975530624, -0.05961501970887184, 0.0271651241928339, -0.036289848387241364, 0.010906144976615906, -0.11617831885814667, 0.016215333715081215, 0.023678556084632874, 1.2276321537902623e-32, -0.054449163377285004, 0.1949332058429718, 0.06841275095939636, -0.09312836080789566, 0.030118536204099655, 0.004520657937973738, 0.09449143707752228, -0.09881720691919327, -0.13625818490982056, -0.12369009852409363, -0.0928436890244484, 0.07497309893369675, -0.06655794382095337, 0.1261587291955948, -0.12316275388002396, -0.2376253306865692, -0.024904146790504456, 0.02719837799668312, 0.13540706038475037, 0.13320277631282806, -0.08203839510679245, -0.019087549299001694, -0.07766499370336533, -0.00924489926546812, -0.14528796076774597, 0.24105128645896912, 0.03316750377416611, 0.05392679199576378, 0.1762738823890686, 0.10072175413370132, -0.06768662482500076, -0.01765749789774418, 0.10272009670734406, -0.07201211154460907, -0.03108436055481434, 0.10824369639158249, 0.1468963623046875, -0.054511263966560364, 0.09344614297151566, -0.13517819344997406, -0.016854440793395042, 0.15106455981731415, -0.21123024821281433, -0.08202669769525528, -0.051486387848854065, 0.03656051307916641, -0.028564956039190292, 0.004991801455616951, -0.031692564487457275, -0.21134689450263977, -0.03970382735133171, 0.16610348224639893, -0.23012469708919525, 0.08902048319578171, -0.11906769871711731, 0.012481885962188244, -0.05538554489612579, -0.05495229363441467, 0.20829859375953674, 0.1335313469171524, 0.14181624352931976, 0.1263841837644577, 0.09686273336410522, 0.04414186254143715, -0.08578211814165115, 0.092034712433815, -0.12797009944915771, -0.05114780738949776, -0.07558564841747284, 0.10528054088354111, 0.014784760773181915, 0.083681121468544, 0.06796720623970032, -0.028345635160803795, -0.05770108476281166, -0.0056447917595505714, 0.02321746200323105, -0.018635356798768044, 0.1816929429769516, 0.1984199732542038, -0.020039152354002, -0.05327802896499634, -0.059029895812273026, 0.10425883531570435, 0.08835763484239578, 0.07315952330827713, 0.069571852684021, 0.02655673399567604, -0.19551287591457367, 0.01301768608391285, 0.09081565588712692, 0.15096300840377808, -0.007307961583137512, 0.016867825761437416, 0.030063500627875328, -1.4707165244218403e-32, 0.00017681033932603896, 0.051148805767297745, 0.1542833000421524, -0.08751684427261353, -0.054642416536808014, -0.011851050890982151, -0.15780165791511536, 0.1810954213142395, 0.17054229974746704, 0.14030155539512634, 0.07652977108955383, 0.05243874341249466, -0.14361855387687683, 0.05020618066191673, 0.012073606252670288, -0.07471416890621185, -0.05491775646805763, -0.1356065422296524, -0.10624639689922333, -0.03788277134299278, -0.09664607048034668, 0.16526354849338531, -0.19096186757087708, 0.15668518841266632, 0.033282238990068436, 0.05332168564200401, -0.0652351975440979, 0.1435045301914215, 0.032424572855234146, 0.06036582216620445, -0.03150676190853119, -0.03978937491774559, -0.14045749604701996, 0.06133308634161949, 0.013431697152554989, 0.04343460500240326, 0.21785593032836914, 0.10163052380084991, -0.0006742764380760491, -0.08774451166391373, 0.013647709041833878, -0.08690343052148819, -0.08551578223705292, 0.061911311000585556, 0.08019782602787018, -0.09322720021009445, -0.074102483689785, -0.2441796511411667, 0.23656755685806274, 0.057807084172964096, -0.025820381939411163, -0.04129099100828171, 0.06068890541791916, 0.055432405322790146, -0.2260395586490631, -0.04558722302317619, 0.09587545692920685, -0.018750522285699844, 0.06971482932567596, -0.15106986463069916, 0.0075324345380067825, 0.21861861646175385, -0.2255026400089264, -0.058680951595306396, 0.05920067057013512, 0.03553543984889984, 0.05094294622540474, -0.2407865673303604, -0.07421562075614929, -0.07395683228969574, -0.011269551701843739, 0.007593466434627771, -0.014164282940328121, -0.1366541087627411, -0.03525860980153084, 0.1754526048898697, -0.032237447798252106, -0.0459836982190609, 0.03186442703008652, -0.07877574115991592, 0.07103557884693146, -0.14920152723789215, 0.03794192895293236, -0.08891867846250534, 0.04227985441684723, -0.12230592221021652, 0.13619659841060638, -0.016309065744280815, -0.1036997139453888, 0.1770123541355133, -0.21361282467842102, -0.15935055911540985, -0.10938936471939087, 0.03547166660428047, 0.040120597928762436, -1.0088099600125133e-07, -0.06633839011192322, -0.09456775337457657, -0.11292210966348648, -0.08274860680103302, -0.036862075328826904, 0.08099833875894547, -0.015172173269093037, 0.006041059270501137, 0.12120546400547028, 0.2070755809545517, 0.17744214832782745, 0.002330798888579011, -0.12454359233379364, 0.0018654895247891545, -0.15215404331684113, -0.023030567914247513, -0.01071312464773655, 0.020017392933368683, 0.014004548080265522, -0.12521445751190186, -0.11033625155687332, 0.22544386982917786, 0.20827922224998474, -0.12607215344905853, 0.042862843722105026, -0.03840971365571022, -0.11717744171619415, 0.09331867098808289, -0.06983843445777893, -0.05556706711649895, -0.04954330995678902, -0.05236541107296944, 0.007838817313313484, 0.14696833491325378, 0.10227633267641068, -0.012653104029595852, -0.09584754705429077, 0.2294849008321762, -0.019581733271479607, 0.10931622982025146, 0.020485416054725647, -0.08794654905796051, -0.07626406848430634, -0.003879992524161935, 0.029923034831881523, -0.05589139088988304, -0.1455409973859787, -0.10307250916957855, 0.0981430783867836, -0.04732118919491768, 0.036051660776138306, -0.033362217247486115, 0.10323342680931091, -0.20338177680969238, -0.20888206362724304, 0.17743812501430511, -0.05964480713009834, 0.10295462608337402, -0.21187320351600647, 0.12439391016960144, 0.049605824053287506, -0.3076218068599701, 0.04969640448689461, 0.04396016150712967], "changes": {"1wk": 47.55555612069589, "1mo": 21.18518970630787}}, {"text": "Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares Candel Therapeutics Tue, Dec 17, 2024, 12:01 AM 5 min read In This Article: CADL +1.13% Candel Therapeutics NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (\u201cCandel\u201d) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the closing of its previously announced underwritten public offering of 12,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The 12,000,001 shares of common stock sold in the offering include 2,000,000 shares sold pursuant to the full exercise of the underwriters\u2019 option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Candel are approximately $92 million, before deducting underwriting discounts and commissions and other offering expenses. Candel intends to use the net proceeds from the offering to continue the development of its product candidates, including preparing submission of a Biologics License Application for CAN-2409 in prostate cancer and for general corporate purposes. Citigroup, BofA Securities and Canaccord Genuity acted as joint bookrunning managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering. A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on August 5, 2022 and declared effective by the SEC on August 12, 2022. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC\u2019s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or telephone: 1-800-831-9146; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, email: dg.prospectus_requests@bofa.com; or Canaccord\u00a0Genuity LLC, Attention: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com. Story Continues This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Candel Therapeutics Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2) and borderline resectable pancreatic ductal adenocarcinoma (PDAC) (phase 2), and recently completed phase 2b and phase 3 clinical trials in localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Finally, Candel\u2019s enLIGHTEN\u2122 Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. Forward-Looking Statements Various statements in this release concerning the use of proceeds from the public offering constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Candel\u2019s control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Candel\u2019s stock price and changes in market conditions, as well as those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in the prospectus supplement and registration statement referenced above, Candel\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, filed on March 28, 2024 with the SEC and subsequent filings with the SEC including Candel\u2019s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Candel undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law. Investor Contact: Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. tjenkins@candeltx.com Media Contact: Ben Shannon Vice President ICR Healthcare CandelPR@icrhealthcare.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CADL", "date": "2024-12-16T21:01:00+00:00", "sentiment": {"score": 0.011564016342163086, "confidence": 0.029387416318058968, "probabilities": {"positive": 0.029387416318058968, "negative": 0.01782339997589588, "neutral": 0.9527891278266907}}, "embedding": [-0.09984462708234787, -0.05963534116744995, -0.046923745423555374, -0.09739017486572266, -0.06650210916996002, 0.033897049725055695, -0.015007264912128448, 0.18600715696811676, 0.16324275732040405, 0.12634581327438354, 0.04013248160481453, 0.048953793942928314, 0.05250595510005951, 0.019030259922146797, -0.07199754565954208, -0.04801880940794945, -0.0029994254000484943, -0.02171911485493183, -0.21051593124866486, 0.25786471366882324, 0.0005993880331516266, 0.022580454126000404, -0.059757910668849945, 0.05777972936630249, -0.026647930964827538, -0.14407917857170105, -0.011121483519673347, -0.014432286843657494, -0.13765539228916168, -0.07799079269170761, 0.06782665848731995, 0.06033629924058914, 0.047460343688726425, -0.02311655320227146, 0.07485795021057129, -0.04513262212276459, -0.1400032490491867, -0.02206546813249588, 0.014176810160279274, 0.021320994943380356, -0.03343774378299713, -0.016457591205835342, -0.19673877954483032, 0.13316363096237183, 0.03766433894634247, -0.10490894317626953, -0.08651791512966156, 0.059205517172813416, 0.10892615467309952, 0.06776189804077148, -0.12092237174510956, -0.1011863648891449, -0.03352804481983185, -0.051770471036434174, -0.06089744716882706, -0.054817140102386475, -0.22529113292694092, -0.057018108665943146, -0.04426271468400955, 0.043823275715112686, 0.044785160571336746, -0.04139368236064911, -0.07661417126655579, 0.04944680631160736, 0.13391555845737457, 0.002651363844051957, 0.06124352663755417, 0.015931690111756325, 0.01356074120849371, -0.022912852466106415, 0.21713581681251526, 0.021330654621124268, 0.001575625967234373, 0.04911511391401291, -0.11934652924537659, 0.05910198763012886, 0.07765382528305054, 0.07893534004688263, 0.09529304504394531, -0.2074572741985321, 0.019863126799464226, 0.08539359271526337, -0.030169762670993805, -0.1302945762872696, -0.02847779169678688, -0.06960958987474442, 0.016080697998404503, 0.1463140845298767, 0.1730625331401825, -0.033297136425971985, 0.06989800184965134, -0.046185169368982315, -0.03184594213962555, -0.044987887144088745, -0.11830628663301468, -0.004085917957127094, -0.03733615204691887, 0.04370858520269394, 0.04623683542013168, 0.029551662504673004, 0.06590031832456589, -0.03591948002576828, 0.029525151476264, -0.09684354066848755, -0.0910787433385849, -0.10158061981201172, 0.01787206158041954, -0.061591293662786484, 0.02553512342274189, 0.03439059853553772, -0.15273813903331757, 0.038262806832790375, -0.04294285178184509, -0.022588122636079788, -0.08372470736503601, 0.15506869554519653, 0.06651216745376587, -0.032905422151088715, 0.158518984913826, -0.12313485890626907, 0.04048437252640724, 0.013590581715106964, 0.06488692760467529, -0.13429434597492218, -0.034581273794174194, -0.034711167216300964, -0.08097127079963684, 7.524248238801274e-33, -0.05665445327758789, 0.019266115501523018, -0.029785579070448875, 0.01728416234254837, -0.0070442138239741325, 0.036098312586545944, 0.07122477144002914, 0.019185669720172882, -0.18098688125610352, -0.02696547843515873, -0.07102634012699127, 0.08116715401411057, 0.004418686497956514, -0.00481459591537714, -0.07120588421821594, -0.07697612047195435, 0.05704083666205406, 0.10355890542268753, 0.062488533556461334, 0.022611629217863083, 0.06898100674152374, 0.07843654602766037, -0.05680655688047409, 0.09073153138160706, -0.12310276925563812, 0.07603570818901062, -0.034738242626190186, 0.007757511455565691, 0.04276737943291664, 0.02895503118634224, 0.06318524479866028, 0.03274759650230408, -0.011918915435671806, -0.067600779235363, 0.04606255888938904, -0.01156691089272499, 0.038823746144771576, -0.054753437638282776, 0.17630088329315186, 0.032546717673540115, -0.030927667394280434, 0.08302091062068939, -0.03861977905035019, -0.15198351442813873, -0.07134807109832764, -0.025705134496092796, -0.07469537109136581, 0.03437390178442001, -0.005984880030155182, 0.021924126893281937, -0.05348435416817665, 0.046211838722229004, -0.09854928404092789, -0.026809055358171463, -0.038285933434963226, -0.0005806619301438332, -0.16626742482185364, -0.029984060674905777, 0.07264125347137451, 0.1475386768579483, 0.007894128561019897, 0.15757623314857483, -0.046242933720350266, 0.10798060148954391, -0.1715271770954132, 0.014283334836363792, -0.11637042462825775, -0.046308599412441254, 0.022805603221058846, 0.105828657746315, -0.09456178545951843, 0.0044077117927372456, 0.005127944052219391, -0.13550466299057007, 0.03678252920508385, -0.08998310565948486, 0.09976419806480408, 0.037736594676971436, 0.07076439261436462, 0.05539672449231148, -0.04414708912372589, -0.01573084108531475, -0.07091493904590607, 0.1383989304304123, -0.03998161852359772, 0.02086576074361801, 0.030135860666632652, 0.02751315012574196, -0.14992520213127136, -0.035401441156864166, 0.10494989901781082, -0.05525801703333855, -0.046969421207904816, 0.07506237179040909, 0.12655502557754517, -8.98170107271561e-33, -0.02841837704181671, -0.03235913813114166, 0.011295408010482788, -0.08894436061382294, 0.021107755601406097, 0.109549880027771, 0.09315347671508789, -0.10620684921741486, -0.021218057721853256, -0.034936390817165375, -0.07576067745685577, 0.044474296271800995, -0.038214534521102905, 5.1225535571575165e-05, -0.1147831603884697, -0.025332361459732056, 0.015799619257450104, 0.017606288194656372, -0.015836751088500023, 0.024596238508820534, -0.05854180455207825, 0.22690477967262268, -0.035987190902233124, 0.05803332105278969, -0.022141313180327415, 0.09622801840305328, 0.001577882096171379, 0.13487163186073303, 0.05585859343409538, 0.04934937134385109, 0.03642997145652771, -0.04568870738148689, -0.1942506730556488, 0.077509805560112, -0.07818587124347687, -0.09055201709270477, 0.13938835263252258, -0.021191824227571487, 0.03225131705403328, -0.0015868684276938438, 0.09971178323030472, -0.002715338720008731, 0.0722554624080658, 0.03043987601995468, 0.034377746284008026, -0.08628849685192108, 0.09458267688751221, -0.20830950140953064, 0.18067359924316406, 0.06579960882663727, 0.0043812645599246025, -0.024638060480356216, 0.037634726613759995, 0.0744079053401947, -0.1399255245923996, -0.02686828374862671, 0.028530683368444443, -0.05743524804711342, 0.04209855571389198, -0.048650532960891724, 0.08924265205860138, 0.18043607473373413, -0.04510409012436867, -0.0342244915664196, 0.141089528799057, -0.06243545562028885, -0.07072320580482483, -0.11056899279356003, -0.026070144027471542, -0.07871323078870773, -0.12040358781814575, -0.18528687953948975, 0.06831041723489761, -0.14834247529506683, 0.026779962703585625, 0.1822650134563446, 0.011686118319630623, -0.1665782928466797, -0.04176589846611023, -0.01651754416525364, 0.010776401497423649, -0.061075277626514435, 0.033457860350608826, 0.04390175640583038, 0.041692979633808136, -0.00742666982114315, 0.04377991333603859, 0.06069847196340561, -0.05741105228662491, 0.12801921367645264, -0.07018480449914932, -0.062345780432224274, 0.08413480222225189, 0.04276495426893234, -0.03647400811314583, -1.0066727895718941e-07, -0.03656981140375137, -0.06696855276823044, 0.0308619923889637, -0.08824129402637482, 0.09180212020874023, -0.007874295115470886, 0.020832763984799385, -0.01822909526526928, 0.09002333879470825, 0.12400245666503906, 0.17085179686546326, 0.15032562613487244, -0.2062748372554779, 0.04016164317727089, -0.18499332666397095, 0.032345134764909744, -0.115350641310215, -0.019255463033914566, -0.09804216027259827, -0.014390961267054081, -0.1443018913269043, 0.04943675547838211, -0.008614066056907177, -0.042026497423648834, 0.03451795503497124, -0.02084336429834366, -0.02343502640724182, 0.06853937357664108, -0.025393584743142128, 0.03641346096992493, 0.004250009544193745, -0.04130558297038078, 0.10578945279121399, 0.15460027754306793, 0.020099466666579247, -0.08185413479804993, 0.02121158130466938, 0.21704687178134918, 0.002740291878581047, 0.14267687499523163, -0.013249754905700684, -0.03311940282583237, -0.019047383219003677, 0.09064728766679764, 0.10376045107841492, -0.07106895744800568, -0.2225578874349594, -0.02920989692211151, 0.060820117592811584, -0.10764012485742569, 0.010098349303007126, -0.01978459767997265, -0.012715904042124748, -0.025132670998573303, -0.09320267289876938, 0.1640988290309906, -0.0558939129114151, 0.06413740664720535, -0.026167357340455055, 0.030609402805566788, 0.00022577494382858276, -0.26139771938323975, 0.0682227611541748, 0.07882408797740936], "changes": {"1wk": 40.211207477921974, "1mo": 29.9756251389161}}, {"text": "PREMIUM Top Premarket Gainers MT Newswires Wed, Dec 11, 2024, 3:40 PM In This Article: CADL +1.13% RZLVW -18.73% Candel Therapeutic (CADL) shares were up more than two-fold pre-bell Wednesday after the company sai PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CADL", "date": "2024-12-11T12:40:51+00:00", "sentiment": {"score": 0.22471668478101492, "confidence": 0.23482169210910797, "probabilities": {"positive": 0.23482169210910797, "negative": 0.010105007328093052, "neutral": 0.7550732493400574}}, "embedding": [-0.19869732856750488, -0.08805380016565323, -0.05501309782266617, 0.11968952417373657, 0.0037774904631078243, 0.06772036850452423, 0.08241462707519531, 0.08248358964920044, 0.09184311330318451, 0.05820168927311897, 0.05505064129829407, 0.15602020919322968, 0.04217062518000603, 0.055525291711091995, 0.03758234530687332, -0.01418441254645586, 0.16296839714050293, -0.10649685561656952, -0.10386455059051514, 0.06482278555631638, -0.21945659816265106, -0.0600062720477581, -0.043541792780160904, 0.10655035078525543, 0.14886842668056488, -0.20233090221881866, -0.16862016916275024, -0.008301964960992336, 0.06105947867035866, -0.12915778160095215, -0.056292574852705, -0.023072486743330956, 0.051998570561409, -0.013374224305152893, -0.03786754608154297, -0.14385652542114258, -0.029264669865369797, -0.024714363738894463, -0.01821938529610634, -0.033398181200027466, 0.025849558413028717, -0.14312858879566193, -0.1403273642063141, 0.0025794850662350655, -0.11516217887401581, -0.04135839268565178, -0.0394488163292408, 0.05194029584527016, 0.07865434139966965, 0.046902842819690704, -0.021890362724661827, -0.027561981230974197, 0.07780661433935165, -0.17656958103179932, 0.00968286395072937, 0.08267048001289368, -0.20180626213550568, -0.04632909968495369, -0.01847757026553154, 0.015019799582660198, -0.04077649489045143, -0.06976839900016785, -0.1075485348701477, 0.03663632273674011, -0.08431164920330048, 0.04557119682431221, 0.020638881251215935, 0.23687389492988586, 0.08578465133905411, -0.13932791352272034, 0.0944514200091362, 0.003331507323309779, 0.08157426863908768, 0.08188017457723618, 0.06824108958244324, 0.10659396648406982, 0.2588115334510803, -0.013955921865999699, 0.12574002146720886, -0.20260196924209595, -0.09941600263118744, 0.08444064855575562, -0.042473308742046356, 0.01832645945250988, 0.03585043549537659, 0.041412290185689926, -0.0180195439606905, 0.056277595460414886, 0.09473838657140732, -0.10670054703950882, 0.13158036768436432, -0.006023642607033253, -0.1500786989927292, 0.09106608480215073, -0.22214864194393158, 0.032770462334156036, -0.09224461764097214, -0.17361260950565338, -0.07885536551475525, 0.03569610416889191, 0.07399190217256546, 0.040536846965551376, 0.053075503557920456, 0.012520497664809227, -0.08981212228536606, -0.13739578425884247, -0.04630706459283829, 0.1754654496908188, 0.08676768839359283, 0.015088347718119621, 0.014197892509400845, 0.039424095302820206, 0.06866015493869781, -0.10776429623365402, -0.18298764526844025, 0.0531625859439373, -0.1357925683259964, -0.02633563056588173, 0.10317987948656082, -0.154549703001976, 0.002342168241739273, 0.09649886935949326, -0.006873464677482843, 0.013039151206612587, -0.09996407479047775, 0.02239617146551609, 0.08376487344503403, 1.3951157807430557e-32, -0.1046837866306305, 0.1168198361992836, 0.006309169810265303, 0.07922402024269104, 0.02111782692372799, 0.027165235951542854, 0.0605071485042572, -0.10653933882713318, -0.1444939523935318, -0.08893810957670212, -0.0686953067779541, 0.046679530292749405, -0.08484739065170288, 0.03075987659394741, -0.10129889845848083, -0.14898954331874847, -0.07023544609546661, 0.035903193056583405, 0.00898201297968626, 0.06240348517894745, 0.03546072170138359, 0.049243658781051636, -0.07198668271303177, 0.022532455623149872, -0.026237552985548973, 0.10418172925710678, 0.01951279491186142, 0.0035091936588287354, 0.07033796608448029, 0.10401967167854309, 0.024553842842578888, 0.047780249267816544, 0.03388934209942818, -0.06039080396294594, 0.029938137158751488, 0.1441546231508255, 0.05893060937523842, -0.04429139196872711, 0.038892000913619995, -0.10901081562042236, 0.08458925038576126, 0.011623811908066273, -0.221768319606781, -0.08781533688306808, -0.12273889780044556, -0.00354655715636909, -0.1917966604232788, 0.039883315563201904, 0.012656177394092083, -0.09167181700468063, -0.06655877828598022, 0.14159642159938812, -0.1465805172920227, 0.11918961256742477, -0.12748213112354279, 0.06696701049804688, -0.05020340159535408, -0.048388175666332245, 0.2616734802722931, 0.05640421807765961, 0.055163636803627014, 0.08723697066307068, 0.013756888918578625, -0.00846189633011818, -0.17159290611743927, 0.045443639159202576, -0.04433220624923706, -0.1331360787153244, -0.09967942535877228, 0.131717249751091, 0.06397045403718948, 0.1022050529718399, 0.05346045270562172, -0.03737645596265793, -0.010090754367411137, 0.018369313329458237, -0.1641765981912613, 0.029982760548591614, 0.19054952263832092, 0.15693821012973785, 0.06010580435395241, -0.0019800462760031223, 0.0011234430130571127, 0.090919129550457, 0.07301335036754608, 0.0013029886176809669, 0.06867285072803497, -0.07007461041212082, -0.08397968858480453, 0.05193913355469704, 0.045010752975940704, 0.041474759578704834, 0.09406676888465881, 0.0918518453836441, -0.04814261198043823, -1.427314775063986e-32, -0.012936213985085487, 0.012868254445493221, 0.12711411714553833, -0.09993656724691391, 0.04340330511331558, -0.015758058056235313, -0.06102713942527771, 0.10056065768003464, 0.01641310751438141, 0.0963488519191742, 0.1636878103017807, 0.03457779437303543, -0.09522707760334015, 0.06960690021514893, 0.07456816732883453, -0.005698785185813904, 0.07707255333662033, -0.11525874584913254, -0.1391308605670929, 0.018586233258247375, -0.02264554426074028, -0.008089207112789154, -0.2177657037973404, 0.2505583167076111, 0.05026916787028313, 0.04935606196522713, -0.027728721499443054, 0.1901296228170395, 0.025221223011612892, 0.026152772828936577, -0.03061726875603199, 0.043341610580682755, -0.08965884149074554, 0.036973703652620316, -0.01205946784466505, -0.06157302483916283, 0.1657017469406128, 0.13179388642311096, -0.06923764199018478, -0.10086797922849655, 0.09000267088413239, -0.08221224695444107, -0.046669453382492065, 0.13700096309185028, -0.004994580056518316, 0.007041760720312595, 0.022913074120879173, -0.16815124452114105, 0.10825353860855103, 0.10405256599187851, -0.010639050044119358, -0.037355802953243256, 0.1308230310678482, 0.11817540973424911, -0.08372820168733597, 0.029472168534994125, 0.07181081175804138, -0.08541251718997955, 0.04305851086974144, -0.07967770844697952, 0.025956150144338608, 0.10460800677537918, -0.1246456503868103, -0.046694010496139526, 0.03884515166282654, -0.028467947617173195, 0.03996797278523445, -0.14179769158363342, -0.014021003618836403, -0.16552188992500305, 0.01886460930109024, -0.03655422106385231, -0.03007940575480461, -0.2953646183013916, -0.038326773792505264, 0.1333402842283249, -0.028120575472712517, -0.0646648183465004, -0.08319156616926193, -0.02781171351671219, -0.040725696831941605, -0.10097454488277435, 0.060597244650125504, 0.03897376358509064, 0.02077198401093483, 0.006597473286092281, 0.07978241890668869, -0.09511836618185043, -0.08032581210136414, 0.07980792224407196, -0.19590000808238983, -0.11427167803049088, -0.058371059596538544, 0.048286665230989456, 0.04923233389854431, -1.0015619267278453e-07, -0.08235946297645569, -0.11508318036794662, -0.0800662413239479, -0.09546220302581787, 0.04071233421564102, 0.03264741227030754, 0.03320641070604324, 0.03949235752224922, 0.018329961225390434, 0.26031693816185, 0.08697569370269775, 0.04141722992062569, -0.12964598834514618, -0.09447573870420456, -0.0718030333518982, -0.019892185926437378, -0.03478009253740311, 0.04416334256529808, -0.01492591854184866, -0.18656255304813385, 0.010838029906153679, 0.18120618164539337, 0.2693606913089752, -0.21098996698856354, -0.014241060242056847, -0.07782755047082901, -0.030916675925254822, 0.023137841373682022, 0.06569546461105347, -0.10301331430673599, -0.06210919842123985, 0.013736022636294365, 0.025902895256876945, 0.11804057657718658, 0.13918229937553406, 0.07847769558429718, 0.05987870320677757, 0.13491158187389374, -0.010874878615140915, 0.1258421242237091, 0.011360658332705498, -0.037982210516929626, 0.061227764934301376, 0.06581582874059677, -0.028464773669838905, -0.0435837022960186, -0.1638024002313614, -0.11249842494726181, 0.14435765147209167, -0.09598173946142197, 0.04940028116106987, -0.06678097695112228, 0.048813194036483765, -0.12832970917224884, -0.2177009880542755, 0.17900000512599945, -0.12034264951944351, 0.04329395666718483, -0.1310204416513443, 0.08146441727876663, 0.08428157866001129, -0.23563475906848907, 0.013688528910279274, 0.11436405777931213], "changes": {"1wk": -14.83871090796686, "1mo": 12.645155383694556}}, {"text": "PREMIUM Candel Therapeutics Says Prostate Cancer Drug Trial Meets Primary Endpoint; Shares Jump MT Newswires Wed, Dec 11, 2024, 3:48 PM In This Article: CADL +1.13% Candel Therapeutics (CADL) shares climbed by more than 120% in premarket trading after the biopharma PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CADL", "date": "2024-12-11T12:48:22+00:00", "sentiment": {"score": 0.14453917555510998, "confidence": 0.1554979532957077, "probabilities": {"positive": 0.1554979532957077, "negative": 0.010958777740597725, "neutral": 0.8335433006286621}}, "embedding": [-0.10204556584358215, -0.13078853487968445, -0.1459711790084839, -0.020540157333016396, 0.03186151757836342, 0.011997680179774761, -0.06648516654968262, 0.13259725272655487, 0.1515006572008133, 0.10569796711206436, -0.016490507870912552, 0.21444562077522278, -0.051810115575790405, 0.14796680212020874, 0.05110705643892288, -0.010209044441580772, 0.07538719475269318, -0.09832233190536499, -0.03188105672597885, 0.2016356736421585, -0.133248433470726, -0.08354291319847107, -0.026537064462900162, 0.16798867285251617, 0.0738152414560318, -0.17923371493816376, -0.09276363253593445, -0.015426956117153168, -0.021727945655584335, -0.11476525664329529, -0.004548208322376013, -0.014801742509007454, 0.0003088498779106885, -0.017757857218384743, 0.05382775887846947, -0.16600683331489563, -0.1118093803524971, -0.018798762932419777, -0.035974983125925064, -0.06213047727942467, 0.06866089999675751, -0.15935306251049042, -0.21001124382019043, 0.10708221048116684, -0.0634932816028595, -0.1636880338191986, -0.11621544510126114, 0.05008293688297272, 0.14504192769527435, 0.14267919957637787, -0.09444445371627808, -0.0957881361246109, 0.05540085211396217, -0.12539878487586975, 0.034354038536548615, -0.012630091048777103, -0.15041577816009521, -0.08555519580841064, -0.019968440756201744, -0.0024046122562140226, -0.012076541781425476, -0.08731815963983536, -0.13941065967082977, 0.04970736429095268, -0.03239922598004341, 0.03835438936948776, -0.04531392455101013, 0.21090131998062134, 0.03440196067094803, -0.07732487469911575, 0.0630507618188858, -0.006021213252097368, 0.07944992929697037, 0.11333809047937393, 0.04923355206847191, 0.026878226548433304, 0.15195679664611816, 0.11031629890203476, 0.1196567639708519, -0.21239812672138214, -0.03273238241672516, 0.06603045761585236, -0.03341319039463997, 0.05588197708129883, -0.0005854933406226337, -0.010285059921443462, -0.003786268178373575, 0.13436006009578705, 0.057873427867889404, -0.13257820904254913, 0.1654502898454666, 0.03336955979466438, -0.09673786163330078, 0.061545759439468384, -0.27665776014328003, -0.026021884754300117, -0.08304337412118912, -0.11707668751478195, -0.07627657800912857, -0.021374013274908066, 0.037336938083171844, 0.04388224706053734, -0.013969801366329193, -0.11041419208049774, -0.1847972869873047, -0.1193310022354126, -0.03571413457393646, 0.05871788412332535, 0.03650772199034691, 0.05108102038502693, -0.015421385876834393, 0.010217970237135887, 0.06988821923732758, -0.02453955076634884, -0.17224082350730896, 0.10274499654769897, -0.1608957201242447, -0.05547793582081795, 0.08404053747653961, -0.09839067608118057, -0.08947538584470749, 0.09635568410158157, 0.03887995332479477, 0.020195700228214264, -0.05836726352572441, 0.10886332392692566, 0.03151402994990349, 1.3928672069867265e-32, 0.029763508588075638, 0.04689563810825348, 0.06282053142786026, 0.05060085654258728, 0.030101528391242027, 0.06986667215824127, 0.13333392143249512, -0.1621411144733429, -0.14780311286449432, -0.23654398322105408, -0.09137476235628128, 0.04918165132403374, -0.06552704423666, 0.07228042185306549, -0.17091208696365356, -0.16340896487236023, 0.006079506129026413, 0.07826235145330429, -0.01024780422449112, 0.06253201514482498, -0.0006858268170617521, 0.04527388513088226, -0.09702727943658829, 0.005569028668105602, -0.13011011481285095, 0.18773473799228668, -0.05252886936068535, 0.01890154555439949, 0.11190062761306763, 0.12534622848033905, -0.03338848054409027, 0.08155126869678497, -0.006919754669070244, -0.07476823031902313, 0.08516289293766022, 0.19091178476810455, 0.11342968791723251, 0.015333418734371662, 0.14071521162986755, -0.001634703716263175, 0.020172899588942528, -0.019848505035042763, -0.10021781176328659, -0.14074824750423431, -0.16175302863121033, 0.020948952063918114, -0.19081641733646393, 0.0044324579648673534, -0.03967267647385597, -0.03714490309357643, -0.0703553855419159, 0.09350337833166122, -0.13271597027778625, 0.02201559580862522, -0.08027718961238861, 0.04402482137084007, -0.196395605802536, -0.08128762245178223, 0.16699719429016113, 0.0765867531299591, 0.13377264142036438, 0.11427249759435654, 0.007855947129428387, 0.04603515937924385, -0.2127164602279663, 0.04850076511502266, -0.14742888510227203, -0.11477802693843842, -0.09710107743740082, 0.23815061151981354, -0.012344151735305786, 0.18428197503089905, 0.08858597278594971, -0.03189747780561447, -0.04044567421078682, 0.013046223670244217, -0.04367419704794884, 0.06757068634033203, 0.1137528270483017, 0.201251819729805, -0.04923486337065697, -0.11920038610696793, -0.06984009593725204, 0.10125472396612167, -0.011663769371807575, 0.044406138360500336, 0.05522211268544197, -0.02731929160654545, -0.22166824340820312, 0.04726872220635414, 0.0049202353693544865, -0.05182414501905441, 0.10028859227895737, 0.16586920619010925, 0.028682423755526543, -1.740745209220982e-32, -0.003187585389241576, -0.007684934418648481, 0.21875925362110138, -0.10697391629219055, 0.045537855476140976, 0.036787211894989014, -0.010439648292958736, -0.01113586314022541, 0.10582044720649719, 0.22846271097660065, 0.11686079949140549, 0.09576767683029175, -0.06874793022871017, 0.09276431798934937, 0.042640745639801025, -0.03409601375460625, 0.03865795582532883, -0.14492255449295044, -0.12088800221681595, -0.05419919267296791, -0.08017600327730179, 0.08921258896589279, -0.18876953423023224, 0.24239160120487213, 0.04404109716415405, 0.0583108589053154, -0.0377417728304863, 0.11392948031425476, 0.05055684596300125, -0.033154990524053574, 0.007495090365409851, 0.12006083875894547, -0.1938144713640213, 0.02159670554101467, -0.00527834240347147, -0.01872309111058712, 0.0773906335234642, 0.01739356480538845, -0.016309289261698723, -0.09943028539419174, 0.07280779629945755, -0.055467765778303146, -0.03453909233212471, 0.05550015717744827, 0.07368211448192596, 0.016293248161673546, -0.012274819426238537, -0.06871873140335083, 0.2649998366832733, 0.08873361349105835, -0.03800263628363609, 0.03795580938458443, 0.11083554476499557, 0.08763668686151505, -0.09663087129592896, -0.06351379305124283, 0.06052780896425247, -0.06736046075820923, -0.02349395491182804, -0.10000623762607574, -0.013900499790906906, 0.1386662870645523, -0.15588977932929993, -0.0313565768301487, -0.0047656819224357605, -0.04805605858564377, -0.006981319282203913, -0.1982301026582718, 0.040020961314439774, -0.05988180264830589, 0.03365930914878845, -0.03209471330046654, -0.027920853346586227, -0.15472407639026642, -0.07181435078382492, 0.1675916612148285, -0.016224322840571404, -0.1054084375500679, -0.09223703294992447, -0.02592379041016102, 0.0419171117246151, -0.147705540060997, 0.06376220285892487, -0.018854789435863495, -0.008893456310033798, 0.07006258517503738, 0.06235431507229805, -0.04053797945380211, -0.09635794907808304, 0.09638785570859909, -0.2069867104291916, -0.14666402339935303, -0.06945990025997162, 0.03724229708313942, 0.04303395748138428, -1.0071666167732474e-07, -0.05849478766322136, -0.141648530960083, 0.014145679771900177, -0.07794802635908127, -0.060908373445272446, 0.07113951444625854, 0.008961420506238937, 0.05453924462199211, 0.13088440895080566, 0.19502456486225128, 0.08175614476203918, 0.07079318910837173, -0.13869300484657288, -0.03494526818394661, -0.12924891710281372, 0.044656507670879364, 0.08378291875123978, 0.04709756746888161, 0.0077466657385230064, -0.1792398989200592, -0.13660193979740143, 0.09292402118444443, 0.16900472342967987, -0.16634486615657806, -0.04637652263045311, -0.003606898942962289, -0.061288200318813324, 0.049734681844711304, 0.01032296009361744, -0.14245741069316864, 0.02785521000623703, -0.05421004071831703, 0.00513866264373064, 0.17168687283992767, 0.09389524161815643, 0.059384413063526154, 0.0926608294248581, 0.1404183804988861, 0.0055157202295959, 0.1273203045129776, 0.07617880403995514, -0.03796845301985741, 0.0021115692798048258, 0.026844965294003487, -0.08636528998613358, -0.08016406744718552, -0.04256858304142952, -0.08486511558294296, 0.09243768453598022, -0.06077801063656807, 0.021168801933526993, -0.07584361732006073, 0.057507678866386414, -0.18339349329471588, -0.1371680647134781, 0.2743676006793976, -0.18953485786914825, 0.0162244513630867, -0.11087241023778915, 0.003522423794493079, 0.15663079917430878, -0.25491559505462646, 0.05231890082359314, 0.16860707104206085], "changes": {"1wk": -14.83871090796686, "1mo": 12.645155383694556}}, {"text": "Candel Therapeutics Announces Pricing of Public Offering Candel Therapeutics Fri, Dec 13, 2024, 7:00 AM 5 min read In This Article: CADL +1.13% Candel Therapeutics NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (\u201cCandel\u201d) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 10,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Candel are expected to be approximately $80 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about December 16, 2024, subject to customary closing conditions. In addition, Candel has granted the underwriters a 30-day option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the underwriting discount. Candel intends to use the net proceeds from the offering to continue the development of its product candidates, including preparing submission of a Biologics License Application for CAN-2409 in prostate cancer and for general corporate purposes. Citigroup, BofA Securities and Canaccord Genuity are acting as joint bookrunning managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering. A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on August 5, 2022 and declared effective by the SEC on August 12, 2022. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC\u2019s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or telephone: 1-800-831-9146; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, email: dg.prospectus_requests@bofa.com; or Canaccord\u00a0Genuity LLC, Attention: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com. Story Continues This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Candel Therapeutics Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2) and borderline resectable pancreatic ductal adenocarcinoma (PDAC) (phase 2), and recently completed phase 2b and phase 3 clinical trials in localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Finally, Candel\u2019s enLIGHTEN\u2122 Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. Forward-Looking Statements Various statements in this release concerning the timing and completion of the public offering on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Candel\u2019s control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Candel\u2019s stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering, as well as those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in the prospectus supplement and registration statement referenced above, Candel\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, filed on March 28, 2024 with the SEC and subsequent filings with the SEC including Candel\u2019s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that Candel will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Candel undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law. Investor Contact: Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. tjenkins@candeltx.com Media Contact: Ben Shannon Vice President ICR Healthcare CandelPR@icrhealthcare.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CADL", "date": "2024-12-13T04:00:00+00:00", "sentiment": {"score": 0.018230928108096123, "confidence": 0.03443412482738495, "probabilities": {"positive": 0.03443412482738495, "negative": 0.016203196719288826, "neutral": 0.9493627548217773}}, "embedding": [-0.13139154016971588, -0.028235699981451035, -0.06024633347988129, -0.0858602225780487, -0.07873547077178955, 0.030430087819695473, 0.00286977831274271, 0.18535301089286804, 0.16336765885353088, 0.1437324583530426, 0.0626431554555893, 0.02741038240492344, 0.052332282066345215, 0.025463394820690155, -0.07750092446804047, -0.05908391252160072, 0.021825101226568222, -0.02188066393136978, -0.2063184231519699, 0.2787783145904541, 0.013320780359208584, -0.006134863942861557, -0.06585796177387238, 0.04782956838607788, -0.012604137882590294, -0.17073222994804382, 0.015835626050829887, -0.029464799910783768, -0.11574575304985046, -0.07957404106855392, 0.0721493735909462, 0.06492569297552109, 0.03140396997332573, -0.01429000310599804, 0.10257543623447418, -0.04067442566156387, -0.1325346976518631, -0.020108763128519058, 0.0029680244624614716, 0.055273864418268204, -0.05399235710501671, -0.029536353424191475, -0.1948544830083847, 0.12919360399246216, 0.03341040015220642, -0.13723987340927124, -0.07716867327690125, 0.08241443336009979, 0.11626136302947998, 0.07135245949029922, -0.10692616552114487, -0.08428362756967545, -0.0313279815018177, -0.06947413086891174, -0.09568347036838531, -0.045213907957077026, -0.21155649423599243, -0.06279365718364716, -0.024218212813138962, 0.02711639180779457, 0.014542274177074432, -0.05419052764773369, -0.06993862986564636, 0.05736596882343292, 0.14110103249549866, 0.03388714790344238, 0.0705287754535675, 0.025059126317501068, 0.010599061846733093, -0.029138833284378052, 0.21990467607975006, 0.0033224113285541534, -0.028607485815882683, 0.03832624852657318, -0.10126300901174545, 0.07258758693933487, 0.09760923683643341, 0.09554994106292725, 0.1156187430024147, -0.235202819108963, 0.03616098687052727, 0.09521157294511795, -0.035140976309776306, -0.13932916522026062, -0.014392653480172157, -0.08000457286834717, 0.029058944433927536, 0.17403152585029602, 0.1908303201198578, -0.019934268668293953, 0.08160644769668579, -0.048641469329595566, -0.0509551465511322, -0.04411288723349571, -0.109660305082798, 0.010605026967823505, -0.04306945577263832, 0.0073959860019385815, 0.047724127769470215, 0.04716441407799721, 0.07353287190198898, -0.07265371084213257, 0.009647371247410774, -0.06660780310630798, -0.09599891304969788, -0.11156010627746582, 0.02659211866557598, -0.057787343859672546, 0.01983765885233879, 0.03099176660180092, -0.1387140154838562, 0.01885407790541649, -0.027979988604784012, -0.042841874063014984, -0.08811505138874054, 0.16127392649650574, 0.0579158179461956, -0.039873939007520676, 0.1619475781917572, -0.15764477849006653, 0.05398954078555107, 0.03020014986395836, 0.05651874095201492, -0.13403227925300598, -0.052315957844257355, -0.03826350346207619, -0.08470944315195084, 8.66783379547049e-33, -0.06310219317674637, 0.013912703841924667, -0.018961844965815544, -0.029526449739933014, -0.028329094871878624, 0.03400784358382225, 0.1000346913933754, 0.020523319020867348, -0.17265331745147705, -0.055171262472867966, -0.0706014558672905, 0.08870469778776169, -0.017168808728456497, -0.05083712190389633, -0.07321447134017944, -0.09543158859014511, 0.07292739301919937, 0.11936155706644058, 0.06972017884254456, 0.02020268142223358, 0.0645359680056572, 0.02276388183236122, -0.03944078087806702, 0.07071513682603836, -0.11022136360406876, 0.04184103012084961, -0.05580345541238785, -0.02919582836329937, 0.05650761350989342, 0.032992348074913025, 0.09084893763065338, 0.037296634167432785, -0.015598013065755367, -0.07556552439928055, 0.03793415427207947, -0.014267578721046448, 0.01948988437652588, -0.04333995282649994, 0.15344274044036865, 0.03910037875175476, -0.05678779259324074, 0.09408925473690033, -0.005678765941411257, -0.1609906703233719, -0.08827066421508789, -0.03265635669231415, -0.056715648621320724, 0.05827485769987106, -0.004123494029045105, 0.00210452638566494, -0.06672273576259613, 0.03946278244256973, -0.09962986409664154, -0.04195248335599899, -0.03711302578449249, 0.009683503769338131, -0.14606182277202606, -0.03268979489803314, 0.06908048689365387, 0.1497250348329544, 0.02117593213915825, 0.14342886209487915, -0.0728798359632492, 0.10114669799804688, -0.18490645289421082, 0.031674824655056, -0.1318933665752411, -0.026526059955358505, 0.03600624203681946, 0.09411770105361938, -0.09251301735639572, 0.001507877605035901, 0.04648682475090027, -0.13679003715515137, 0.03230024874210358, -0.05739634484052658, 0.11103489995002747, 0.05137883126735687, 0.057691458612680435, 0.04552934691309929, -0.08010963350534439, -0.023701753467321396, -0.08072779327630997, 0.1385674774646759, -0.03669172525405884, 0.039378173649311066, 0.03595596179366112, 0.027693897485733032, -0.13292352855205536, -0.024136394262313843, 0.10677586495876312, -0.04369974881410599, -0.05533111095428467, 0.08517438173294067, 0.15009763836860657, -9.422701002738038e-33, -0.025809448212385178, -0.017248377203941345, 0.014531537890434265, -0.09593331068754196, 0.05027368664741516, 0.10590667277574539, 0.046648379415273666, -0.1122061163187027, -0.0200461708009243, -0.045816197991371155, -0.1082017719745636, 0.06119564175605774, -0.036005549132823944, 0.0032427143305540085, -0.10122901201248169, -0.03926199674606323, -0.006464233621954918, -0.0013393505942076445, -0.03129307180643082, 0.0255122072994709, -0.09462442994117737, 0.25184184312820435, -0.035138849169015884, 0.04659572243690491, -0.011371323838829994, 0.1103987842798233, 0.0023930296301841736, 0.14901460707187653, 0.05011199787259102, 0.06718005239963531, 0.024151882156729698, -0.04335058480501175, -0.2133978307247162, 0.06871827691793442, -0.07286007702350616, -0.086753249168396, 0.14369253814220428, -0.0005232570692896843, 0.03294062241911888, 0.0110555961728096, 0.09055772423744202, 0.006942832842469215, 0.09198436141014099, 0.016594870015978813, 0.04630208760499954, -0.09259779751300812, 0.09642833471298218, -0.2253742814064026, 0.2041633576154709, 0.07851121574640274, -0.010911866091191769, -0.01269683800637722, 0.06046227365732193, 0.09187465906143188, -0.1645919382572174, -0.022102732211351395, 0.027403071522712708, -0.08729341626167297, 0.04048803448677063, -0.03535962849855423, 0.0944986492395401, 0.18698269128799438, -0.03551200404763222, -0.028845181688666344, 0.12057748436927795, -0.0566435307264328, -0.07721446454524994, -0.11248044669628143, 0.007509792689234018, -0.10026539862155914, -0.10699321329593658, -0.20278100669384003, 0.08389095216989517, -0.1507139801979065, 0.024907056242227554, 0.16863656044006348, 0.0353119820356369, -0.16790837049484253, -0.017526928335428238, -0.0187673456966877, -0.013434559106826782, -0.03200390189886093, -0.007430560886859894, 0.05564511567354202, 0.02762661501765251, -0.02563299424946308, 0.061956584453582764, 0.04399493336677551, -0.0433599129319191, 0.12633386254310608, -0.059947311878204346, -0.0575374960899353, 0.11893351376056671, 0.06227098032832146, -0.045413680374622345, -1.0062210265004978e-07, -0.04967056214809418, -0.06238419562578201, 0.028369657695293427, -0.0566256009042263, 0.09311836957931519, -0.025752317160367966, 0.02886778488755226, -0.05175100266933441, 0.08457687497138977, 0.12118858844041824, 0.1962251365184784, 0.14315570890903473, -0.1797536164522171, 0.027365483343601227, -0.20725834369659424, 0.015780551359057426, -0.12833599746227264, 0.0009877937845885754, -0.11557548493146896, -0.048605628311634064, -0.14463801681995392, 0.0459950752556324, -0.0218442901968956, -0.026250207796692848, 0.03100065514445305, -0.018967781215906143, 0.0019038827158510685, 0.0691235139966011, -0.011411006562411785, 0.061590734869241714, -0.01796565018594265, -0.015167498029768467, 0.11361919343471527, 0.13594336807727814, 0.016752909868955612, -0.09326769411563873, 0.009373987093567848, 0.22057229280471802, 0.01509896107017994, 0.14354801177978516, 0.0037900516763329506, -0.010634087026119232, 0.0009815897792577744, 0.08744609355926514, 0.1082223504781723, -0.071616992354393, -0.2355300933122635, -0.022753020748496056, 0.05830153077840805, -0.10780365020036697, -0.0002275519073009491, -0.012316364794969559, -0.009852967225015163, 0.0004481594078242779, -0.08292952179908752, 0.16911762952804565, -0.04919090121984482, 0.0755210742354393, -0.04454220086336136, 0.0559285432100296, 0.003693286795169115, -0.28078293800354004, 0.08200272917747498, 0.07562527060508728], "changes": {"1wk": 47.55555612069589, "1mo": 21.18518970630787}}, {"text": "Candel Therapeutics Announces $80 Million Proposed Public Offering Candel Therapeutics Fri, Dec 13, 2024, 12:51 AM 5 min read In This Article: CADL +1.13% Candel Therapeutics NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (\u201cCandel\u201d) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the launch of an underwritten public offering of $80 million of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Candel. Candel also intends to grant the underwriters a 30-day option to purchase up to an additional $12 million of the shares of its common stock offered in the public offering under the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Candel intends to use the net proceeds from the offering to continue the development of our product candidates, including preparing the submission of a Biologics License Application for CAN-2409 in prostate cancer and for general corporate purposes. Citigroup, BofA Securities and Canaccord Genuity are acting as joint bookrunning managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering. A shelf registration statement on Form S-3 relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on August 5, 2022 and declared effective by the SEC on August 12, 2022. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC\u2019s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-800-831-9146; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, email: dg.prospectus_requests@bofa.com; or Canaccord\u00a0Genuity LLC, Attention: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Story Continues About Candel Therapeutics Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2) and borderline resectable pancreatic ductal adenocarcinoma (PDAC) (phase 2), and recently completed phase 2b and phase 3 clinical trials in localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Finally, Candel\u2019s enLIGHTEN\u2122 Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. Forward-Looking Statements Various statements in this release concerning the timing, size, structure and completion of the proposed public offering on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Candel\u2019s control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Candel\u2019s stock price, changes in market conditions, the final terms of the public offering and satisfaction of customary closing conditions related to the public offering, as well as those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in the prospectus supplement and registration statement referenced above, Candel\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, filed on March 28, 2024 with the SEC and subsequent filings with the SEC including Candel\u2019s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that Candel will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Candel undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law. Investor Contact: Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. tjenkins@candeltx.com Media Contact: Ben Shannon Vice President ICR\u00a0Healthcare CandelPR@icrhealthcare.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CADL", "date": "2024-12-12T21:51:00+00:00", "sentiment": {"score": 0.01379004679620266, "confidence": 0.030105412006378174, "probabilities": {"positive": 0.030105412006378174, "negative": 0.016315365210175514, "neutral": 0.9535792469978333}}, "embedding": [-0.1543717086315155, -0.0637005865573883, -0.07217052578926086, -0.11363261193037033, -0.11098752915859222, 0.02418970689177513, 0.03186708688735962, 0.19253742694854736, 0.14305293560028076, 0.05753722041845322, 0.059026580303907394, 0.02627178095281124, 0.021024029701948166, 0.029266662895679474, -0.03761937841773033, -0.08014002442359924, 0.011363076977431774, -0.00787297636270523, -0.11247019469738007, 0.23786047101020813, 0.03758684918284416, 0.0034246088471263647, -0.05769195035099983, 0.06768850982189178, -0.058910079300403595, -0.1377161294221878, -0.009504446759819984, -0.0071662780828773975, -0.11636519432067871, -0.06443029642105103, 0.06971616297960281, 0.112785205245018, 0.0657389685511589, -0.014279257506132126, 0.11438485980033875, -0.025199610739946365, -0.14630505442619324, 0.02272336557507515, 0.032707422971725464, 0.03932911902666092, -0.055871158838272095, -0.03149609640240669, -0.12074808776378632, 0.10299605131149292, 0.001475295051932335, -0.12487468123435974, -0.06524723768234253, 0.0605466291308403, 0.07056131958961487, 0.09102986007928848, -0.09924431890249252, -0.03070305660367012, -0.0025622393004596233, 0.00718143954873085, -0.037543438374996185, -0.04032186418771744, -0.20453375577926636, -0.024123435840010643, -0.04712788760662079, 0.05455916374921799, 0.020893394947052002, -0.03851957246661186, -0.04768281430006027, 0.021998025476932526, 0.08464740216732025, 0.07393859326839447, 0.0388004332780838, 0.038418568670749664, -0.027009600773453712, -0.04914650321006775, 0.20702025294303894, -0.03705310449004173, -0.05669841915369034, 0.08507142961025238, -0.11231286823749542, 0.09188329428434372, 0.11609211564064026, 0.11397493630647659, 0.1264941245317459, -0.19444090127944946, 0.01744636334478855, 0.09751269221305847, -0.007065133191645145, -0.08606071770191193, -0.05965973436832428, -0.03158816695213318, -0.006738961674273014, 0.16036128997802734, 0.13747622072696686, -0.01112713199108839, 0.07778328657150269, -0.054976724088191986, -0.04939119517803192, -0.03271309658885002, -0.08931385725736618, -0.008641931228339672, -0.042298756539821625, -0.01223090197890997, 0.04811086878180504, 0.0466887392103672, 0.05384545773267746, -0.06717954576015472, 0.012195639312267303, -0.07504664361476898, -0.09238040447235107, -0.0808335617184639, -0.004658639430999756, -0.060662925243377686, 0.0564296580851078, 0.04698312282562256, -0.14141809940338135, 0.02137836255133152, -0.01818327233195305, -0.03607902303338051, -0.08971947431564331, 0.1297016441822052, 0.014733664691448212, -0.03766889497637749, 0.1847669780254364, -0.1167268380522728, 0.07097132503986359, 0.03732118010520935, 0.028239017352461815, -0.12900933623313904, -0.036525506526231766, 0.026373567059636116, -0.041092123836278915, 8.775497323062303e-33, -0.07553571462631226, 0.0292303878813982, 0.012021675705909729, 0.07983773946762085, -0.02450394630432129, 0.03569766879081726, 0.10718587785959244, 0.012623406015336514, -0.1807035505771637, -0.06907407939434052, -0.09404811263084412, 0.08889995515346527, -0.017635665833950043, -0.04459010437130928, -0.07240195572376251, -0.060972269624471664, 0.054533250629901886, 0.09373009204864502, 0.039580125361680984, 0.005258334334939718, 0.07990298420190811, 0.056025948375463486, -0.037742599844932556, 0.061461545526981354, -0.04700755327939987, 0.018135471269488335, -0.06258988380432129, 0.018389586359262466, 0.06645577400922775, 0.027691448107361794, 0.09016053378582001, 0.050363704562187195, -0.026414642110466957, -0.10020959377288818, 0.04251796752214432, -0.051440563052892685, -0.043764628469944, -0.07253196835517883, 0.09375476092100143, 0.03455045446753502, 0.011423974297940731, 0.08100799471139908, -0.027136599645018578, -0.09037409722805023, -0.03523625433444977, -0.0024115697015076876, -0.056674204766750336, 0.06899811327457428, 0.06315885484218597, 0.015140572562813759, -0.05239152908325195, 0.02076348289847374, -0.10805419832468033, -0.03949816897511482, -0.005845725070685148, 0.0386006236076355, -0.1579374074935913, 0.0012884465977549553, 0.07910510897636414, 0.1286686807870865, -0.0079058101400733, 0.11149546504020691, -0.03760696202516556, 0.0794774666428566, -0.13013151288032532, 0.023659244179725647, -0.13477887213230133, -0.0487765371799469, 0.023447606712579727, 0.058174751698970795, -0.09477098286151886, -0.018939828500151634, 0.05689171329140663, -0.08186770230531693, 0.022667288780212402, -0.11568602919578552, 0.080438531935215, 0.06748034805059433, -0.020886525511741638, 0.050470270216464996, -0.060664910823106766, 0.011316495947539806, -0.04762392118573189, 0.17259471118450165, -0.00730646587908268, 0.019683802500367165, 0.0586213655769825, -0.001461731269955635, -0.10364877432584763, -0.04476854205131531, 0.08475987613201141, -0.03416316956281662, -0.03808155655860901, 0.09303256869316101, 0.07058746367692947, -9.329553361010942e-33, -0.010988363064825535, -0.09455625712871552, 0.025343652814626694, -0.08289115130901337, 0.04229792580008507, 0.0898335799574852, 0.05569670349359512, -0.04621855914592743, -0.003257639706134796, -0.0829145535826683, -0.04023313522338867, 0.03950939327478409, 0.0055248974822461605, -0.039486728608608246, -0.10475050657987595, -0.006500270217657089, -0.03428685665130615, -0.03674370050430298, -0.07636793702840805, 0.03314069285988808, -0.03496253490447998, 0.1420827955007553, -0.053011205047369, 0.04626714438199997, -0.004923462867736816, 0.0966266319155693, 0.03259789198637009, 0.12021423876285553, 0.013988755643367767, 0.07572897523641586, -0.02899690344929695, -0.020225118845701218, -0.23035746812820435, 0.0946466401219368, -0.057114146649837494, -0.12128335237503052, 0.15191784501075745, -0.04810769483447075, -0.0005632741376757622, 0.014392082579433918, 0.06587421894073486, 0.007270257920026779, 0.09236022084951401, 0.04910603165626526, -0.006804050877690315, -0.044886264950037, 0.11286672949790955, -0.1485428810119629, 0.20116904377937317, 0.07779324799776077, -0.015074423514306545, -0.015660393983125687, 0.03902405872941017, 0.07535181939601898, -0.07928633689880371, -0.05251820385456085, 0.025724999606609344, -0.08482421934604645, 0.03842296078801155, -0.04302502050995827, 0.08706054091453552, 0.16947661340236664, -0.008498519659042358, -0.01427021436393261, 0.146000474691391, -0.0401654914021492, -0.09280955791473389, -0.12351144850254059, 0.0024200575426220894, -0.07755007594823837, -0.07527768611907959, -0.17254960536956787, 0.046957001090049744, -0.1326931118965149, 0.021050527691841125, 0.13762778043746948, 0.014084688387811184, -0.15826308727264404, -0.05983099341392517, -0.0380026176571846, 0.0006544319912791252, -0.025746390223503113, -0.021973997354507446, 0.11461011320352554, 0.0673123225569725, -0.015373488888144493, 0.05987963825464249, 0.026683416217565536, -0.011682243086397648, 0.06563897430896759, -0.07070022076368332, -0.0714578703045845, 0.04544667527079582, 0.08093129098415375, -0.00894885417073965, -1.0031832431423027e-07, -0.002526388969272375, -0.06477127969264984, 0.003501980099827051, -0.12778937816619873, 0.07901106774806976, -0.01772228069603443, 0.006022527348250151, -0.04532228037714958, 0.100395068526268, 0.1126696765422821, 0.1365298330783844, 0.17604544758796692, -0.17768490314483643, -0.025457099080085754, -0.16813308000564575, -0.03416717052459717, -0.11332106590270996, -0.02488713152706623, -0.1062166839838028, -0.03906805068254471, -0.14914250373840332, 0.03696255758404732, 0.020075032487511635, -0.022992851212620735, 0.048205066472291946, -0.050589729100465775, -0.01295886654406786, 0.05633878707885742, -0.03760751336812973, 0.05947462469339371, -0.0009337649680674076, -0.03392722085118294, 0.1202903613448143, 0.08807609230279922, 0.016362488269805908, -0.0865759402513504, 0.0017818156629800797, 0.1963219940662384, 0.01811761036515236, 0.1013963520526886, 0.013669178821146488, -0.04691927880048752, -0.013441232964396477, 0.06603890657424927, 0.07104748487472534, -0.0614093653857708, -0.1678616851568222, -0.011445690877735615, 0.0639287531375885, -0.0728779137134552, -0.01744496449828148, -0.020952574908733368, -0.009646650403738022, -0.007186176721006632, -0.1277676522731781, 0.1696932017803192, -0.06611515581607819, 0.02711104042828083, 0.0007567486027255654, 0.012911040335893631, 0.0017635561525821686, -0.19958147406578064, 0.08932216465473175, 0.10193993151187897], "changes": {"1wk": 1.6326514724293246, "1mo": -16.530610755402492}}, {"text": "Candel Therapeutics Stock Surges Over 100% - Here's Why Vandana Singh Wed, Dec 11, 2024, 5:19 PM 2 min read In This Article: CADL +1.13% Candel Therapeutics Stock Surges Over 100% - Here's Why On Wednesday, Candel Therapeutics, Inc. (NASDAQ: CADL ) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients . The trial met its primary endpoint and demonstrated statistically significant improvement in disease-free survival in patients who received CAN-2409 plus the prodrug (valacyclovir) combined with the standard of care compared to the standard of care alone. CAN-2409, when administered with valacyclovir, is designed to induce immunogenic cell death of tumor cells by exposing them to tumor antigens in the context of an activated tumor microenvironment. Key topline results include: Statistically significant improvement in disease-free survival (DFS) for CAN-2409 plus radiation therapy (n=496) vs. radiation therapy alone (n=249) (p=0.0155; HR 0.7) in the intent-to-treat population. At 54 months, the CAN-2409 treatment arm observed a 14.5% relative improvement in DFS compared to the placebo control arm. DFS improvement was observed in patients receiving short-term ADT and those not receiving ADT. In an analysis that focused on prostate-specific outcomes, CAN-2409 showed a highly significant effect on prostate cancer-free survival. A significant increase in the proportion of patients achieving a prostate-specific antigen (PSA) nadir (<0.2 ng/ml) was observed in the treatment arm compared to the placebo control arm (67.1% vs. 58.6%, respectively; p<0.0164). CAN-2409 induced 80.4% pathological complete responses (pCRs) in the 2-year post-treatment biopsies compared to 63.6% observed in the control arm (p=0.0015). The median follow-up time for the recruited population was 50.3 months. The safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identified. The most common CAN-2409-related adverse events were flu-like symptoms, fever and chills, which were generally mild to moderate in severity and self-limited. The company also reported that the phase 2 clinical trial of monotherapy CAN-2409 in 190 patients with low-to-intermediate risk localized prostate cancer undergoing active surveillance. The trial showed numerical improvement in time to radical treatment and the percentage of patients achieving negative (prostate cancer-free) biopsies at 1-year post-treatment. However, these differences did not reach statistical significance. Price Action: CADL stock is up 167.70% at $12.34\u00a0during the premarket session at last check Wednesday. Read Next: Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder Story Continues UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Candel Therapeutics Stock Surges Over 100% - Here's Why originally appeared on Benzinga.com \u00a9 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CADL", "date": "2024-12-11T14:19:44+00:00", "sentiment": {"score": 0.9143898282200098, "confidence": 0.9429011940956116, "probabilities": {"positive": 0.9429011940956116, "negative": 0.02851136587560177, "neutral": 0.028587453067302704}}, "embedding": [-0.041237201541662216, -0.032061174511909485, -0.14420241117477417, -0.15547162294387817, -0.00019614212214946747, -0.04249340295791626, -0.004056289792060852, 0.2834116220474243, 0.1430303454399109, 0.08312132954597473, -0.020132195204496384, 0.18622134625911713, 0.16503947973251343, 0.105583555996418, 0.018982453271746635, 0.024783732369542122, 0.17468354105949402, 0.009861459024250507, -0.0994887426495552, 0.12151798605918884, -0.010328883305191994, -0.08216950297355652, 0.04203564673662186, 0.06576290726661682, -0.06577546149492264, -0.1157643049955368, -0.11471404135227203, 0.06967709213495255, -0.1082715392112732, -0.04080158472061157, 0.04528098925948143, -0.01634296216070652, -0.0664663091301918, -0.005326921585947275, -0.03919488936662674, -0.027589749544858932, -0.14131170511245728, 0.07726825773715973, -0.14715276658535004, 0.011977143585681915, -0.030642949044704437, -0.026132628321647644, -0.09338182210922241, 0.04318050295114517, 0.042946796864271164, -0.17691199481487274, -0.10602836310863495, -0.0515621118247509, 0.054579202085733414, 0.15591996908187866, -0.0014239596202969551, 0.044767819344997406, 0.016207553446292877, 0.09351508319377899, -0.033467378467321396, -0.18258118629455566, -0.13270361721515656, 0.020399296656250954, 0.0024579642340540886, 0.04514482989907265, -0.06524176895618439, -0.11492703855037689, -0.03237566724419594, 0.024213459342718124, 0.04646800458431244, -0.02504284493625164, -0.09504596889019012, -0.03877885639667511, -0.015302218496799469, 0.04232214018702507, 0.08283501118421555, -0.005220762919634581, -0.04060232639312744, -0.016471004113554955, -0.04907580465078354, -0.05518854409456253, 0.11602488905191422, 0.16612403094768524, 0.021851614117622375, -0.07598552852869034, 0.0282454676926136, 0.0759575217962265, 0.02465817891061306, -0.041082628071308136, -0.042562078684568405, -0.03604473918676376, 0.026257850229740143, 0.17567309737205505, 0.07068966329097748, 0.06242061406373978, 0.12726734578609467, 0.08506499230861664, 0.027425616979599, 0.0492108017206192, 0.026708360761404037, -0.08896081149578094, -0.022434810176491737, -0.03402151167392731, 0.017959844321012497, -0.025649286806583405, -0.03667975962162018, -0.11579674482345581, -0.12910319864749908, -0.05688448250293732, -0.11728265881538391, -0.07870516180992126, -0.08982329815626144, -0.04966031759977341, -0.02092640846967697, 0.11310887336730957, -0.015712518244981766, -0.052528172731399536, 0.028193458914756775, 0.018599946051836014, -0.04347917437553406, 0.08094644546508789, -0.006543180905282497, -0.05061443895101547, 0.05359972268342972, -0.12321683019399643, 0.05251450464129448, -0.04885145649313927, 0.11374734342098236, -0.06722041964530945, 0.1003963053226471, 0.24498340487480164, 0.13657942414283752, 6.603979425481429e-33, 0.07610569894313812, 0.00030709337443113327, 0.03010563738644123, 0.010257385671138763, -0.0010810690000653267, 0.040507130324840546, 0.12501932680606842, -0.0206102654337883, -0.00894286297261715, -0.15202350914478302, 0.04924231395125389, 0.0031772705260664225, 0.12027348577976227, -0.011125835590064526, -0.09569264948368073, 0.028133366256952286, 0.07826030254364014, 0.009731009602546692, -0.16977420449256897, 0.01523681078106165, 0.020113859325647354, 0.0069581205025315285, -0.018994232639670372, 0.08071321249008179, -0.06287480890750885, 0.0410749576985836, -0.0194132998585701, 0.12923642992973328, -0.04730051010847092, -0.0029839035123586655, -0.05070791393518448, -0.012296853587031364, -0.004868329502642155, -0.004237835295498371, 0.026205068454146385, 0.015763726085424423, 0.0026736967265605927, 0.002135779708623886, 0.17516249418258667, 0.008430812507867813, 0.05896514654159546, -0.041927315294742584, 0.058466918766498566, -0.044049859046936035, 0.07557694613933563, -0.0796007513999939, -0.05942879989743233, -0.04711580276489258, -0.16052529215812683, 0.03306727856397629, -0.05778105556964874, -0.013904603198170662, -0.062404945492744446, -0.031934164464473724, -0.02820301428437233, 0.06577825546264648, -0.08703891932964325, 0.08717498183250427, 0.03288351744413376, 0.09865570813417435, -0.06051579862833023, -0.010093522258102894, 0.13020633161067963, 0.022280998528003693, -0.047770947217941284, -0.015837235376238823, -0.10457895696163177, -0.08417700976133347, -0.0644846260547638, 0.10267704725265503, -0.05822454392910004, 0.07353337109088898, 0.07027726620435715, 0.03275479003787041, 0.037044502794742584, -0.08028872311115265, 0.03752564638853073, 0.10919640213251114, -0.11237937211990356, 0.10909862816333771, -0.12356288731098175, -0.03569293022155762, -0.15068432688713074, 0.11793563514947891, 0.011160550639033318, -0.036471135914325714, -0.0016042767092585564, -0.06318533420562744, -0.17709332704544067, -0.0549776554107666, 0.10005196928977966, -0.01285296306014061, 0.015008434653282166, 0.06362280249595642, 0.0691002756357193, -1.0318326311676863e-32, 0.017645396292209625, -0.021394997835159302, 0.04245268553495407, -0.03444308787584305, 0.05233217030763626, 0.0707116425037384, 0.021102890372276306, 0.00498094130307436, 0.029641801491379738, -0.10133443772792816, 0.01674756035208702, 0.05866837501525879, -0.08179736137390137, -0.0030581611208617687, -0.18629930913448334, -0.04188847914338112, -0.08450263738632202, 0.002422227757051587, -0.14300158619880676, -0.01697397232055664, -0.023446673527359962, 0.13851717114448547, -0.024335555732250214, 0.101178377866745, -0.06885775923728943, 0.030357535928487778, -0.013355678878724575, 0.03163496404886246, 0.07139597088098526, 0.0018726149573922157, 0.06405435502529144, 0.08551160246133804, -0.1655316948890686, 0.0814395621418953, 0.11038194596767426, -0.031595274806022644, 0.07662519812583923, -0.13839535415172577, 0.02111312747001648, -0.03887557610869408, 0.04042521119117737, 0.08663806319236755, -0.013931633904576302, -0.007076000329107046, 0.034323252737522125, 0.04711529612541199, 0.11375502496957779, -0.04744946211576462, 0.168437659740448, 0.028174083679914474, -0.0739934965968132, -0.06534026563167572, 0.04056769609451294, 0.17767685651779175, -0.03058876469731331, -0.10244160890579224, 0.07220140099525452, 0.004861856810748577, -0.12391195446252823, -0.02239886298775673, 0.017709624022245407, 0.03987672179937363, 0.008026889525353909, -0.038515638560056686, 0.01636635512113571, 0.07993564009666443, 0.01858738251030445, -0.0442190058529377, 0.11915479600429535, -0.10063932836055756, -0.024569567292928696, -0.05535802245140076, -0.0194418802857399, -0.08118139952421188, -0.0663323849439621, 0.10266254842281342, 0.009705696254968643, -0.051561493426561356, -0.045677512884140015, -0.08457529544830322, -0.15971985459327698, -0.0626690685749054, -0.11913600564002991, -0.08574368059635162, 0.0865691602230072, 0.08782052248716354, -0.008390631526708603, -0.12307843565940857, -0.043242987245321274, 0.004061190411448479, -0.04305984452366829, -0.06800024956464767, -0.04508709907531738, 0.041958484798669815, -0.07783949375152588, -1.0073134149024554e-07, 0.09747543931007385, -0.049758896231651306, -0.05984827131032944, -0.1027723103761673, -0.05363617092370987, 0.003776180325075984, -0.029942486435174942, -0.07182293385267258, 0.007183133624494076, 0.11558380722999573, 0.16485773026943207, 0.07918721437454224, -0.10314203798770905, -0.0045885019935667515, -0.0335303470492363, 0.03888339921832085, 0.05687357857823372, 0.03392481803894043, -0.03104548156261444, -0.01959758624434471, -0.058038175106048584, -0.13781246542930603, -0.019815240055322647, -0.0472843311727047, -0.043283313512802124, 0.06445418298244476, 0.07177312672138214, 0.07316866517066956, 0.04547717794775963, -0.13702690601348877, -0.01839631050825119, -0.15897807478904724, -0.0003886530175805092, 0.04895775765180588, 0.042247287929058075, 0.004531883634626865, 0.12207812070846558, 0.02965094894170761, 0.1175839751958847, 0.14595262706279755, 0.05273588001728058, -0.00994962640106678, -0.09917643666267395, 0.034935999661684036, -0.07275671511888504, -0.006480415817350149, -0.11694420874118805, -0.08203007280826569, -0.09180645644664764, -0.017669908702373505, -0.03405323624610901, 0.0098551195114851, 0.021582549437880516, -0.09243455529212952, -0.08820529282093048, 0.18044377863407135, -0.016761600971221924, -0.07860679924488068, 0.14106281101703644, 0.03651200234889984, -0.013505689799785614, -0.05613425374031067, 0.039729487150907516, 0.0254619549959898], "changes": {"1wk": -14.83871090796686, "1mo": 12.645155383694556}}]